WO2003012395A2 - Early detection of mycobacterial disease using peptides - Google Patents
Early detection of mycobacterial disease using peptides Download PDFInfo
- Publication number
- WO2003012395A2 WO2003012395A2 PCT/US2002/024297 US0224297W WO03012395A2 WO 2003012395 A2 WO2003012395 A2 WO 2003012395A2 US 0224297 W US0224297 W US 0224297W WO 03012395 A2 WO03012395 A2 WO 03012395A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- antigens
- seq
- kda
- antigen
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 227
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 119
- 238000001514 detection method Methods 0.000 title claims abstract description 53
- 208000027531 mycobacterial infectious disease Diseases 0.000 title claims description 11
- 102000036639 antigens Human genes 0.000 claims abstract description 510
- 108091007433 antigens Proteins 0.000 claims abstract description 509
- 239000000427 antigen Substances 0.000 claims abstract description 500
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 357
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 339
- 238000000034 method Methods 0.000 claims abstract description 79
- 210000002700 urine Anatomy 0.000 claims abstract description 73
- 239000000203 mixture Substances 0.000 claims abstract description 69
- 230000000890 antigenic effect Effects 0.000 claims abstract description 49
- 201000010099 disease Diseases 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 101150047914 mpt51 gene Proteins 0.000 claims abstract description 32
- 229920001184 polypeptide Polymers 0.000 claims abstract description 18
- 230000004927 fusion Effects 0.000 claims abstract description 15
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 12
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 12
- 230000009257 reactivity Effects 0.000 claims description 139
- 210000002966 serum Anatomy 0.000 claims description 89
- 201000008827 tuberculosis Diseases 0.000 claims description 66
- 241000588724 Escherichia coli Species 0.000 claims description 42
- 238000012360 testing method Methods 0.000 claims description 40
- 208000015181 infectious disease Diseases 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 239000003153 chemical reaction reagent Substances 0.000 claims description 25
- 238000006467 substitution reaction Methods 0.000 claims description 17
- 102000037865 fusion proteins Human genes 0.000 claims description 16
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 14
- 230000003902 lesion Effects 0.000 claims description 14
- 239000013060 biological fluid Substances 0.000 claims description 13
- 210000001124 body fluid Anatomy 0.000 claims description 13
- 239000010839 body fluid Substances 0.000 claims description 13
- 206010036790 Productive cough Diseases 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 210000003802 sputum Anatomy 0.000 claims description 11
- 208000024794 sputum Diseases 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 8
- 230000003053 immunization Effects 0.000 claims description 8
- 230000002685 pulmonary effect Effects 0.000 claims description 8
- 101710102499 Alanine and proline-rich secreted protein Apa Proteins 0.000 claims description 6
- 208000036981 active tuberculosis Diseases 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 5
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 229920000570 polyether Polymers 0.000 claims description 3
- 206010062207 Mycobacterial infection Diseases 0.000 claims description 2
- 208000033353 latent tuberculosis infection Diseases 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 41
- -1 variants thereof Proteins 0.000 abstract description 32
- 238000003018 immunoassay Methods 0.000 abstract description 27
- 238000011161 development Methods 0.000 abstract description 16
- 108010033276 Peptide Fragments Proteins 0.000 abstract description 5
- 102000007079 Peptide Fragments Human genes 0.000 abstract description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 321
- 241000725303 Human immunodeficiency virus Species 0.000 description 57
- 239000000499 gel Substances 0.000 description 53
- 239000000706 filtrate Substances 0.000 description 52
- 238000003556 assay Methods 0.000 description 50
- 238000002965 ELISA Methods 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 39
- 238000004458 analytical method Methods 0.000 description 37
- 239000000523 sample Substances 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 31
- 239000012528 membrane Substances 0.000 description 29
- 210000004379 membrane Anatomy 0.000 description 28
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 27
- 239000002953 phosphate buffered saline Substances 0.000 description 27
- 239000006166 lysate Substances 0.000 description 24
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 24
- 101710134638 88 kDa protein Proteins 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 239000000872 buffer Substances 0.000 description 20
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 19
- 102000003992 Peroxidases Human genes 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 230000035945 sensitivity Effects 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 229940098773 bovine serum albumin Drugs 0.000 description 16
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 101150013110 katG gene Proteins 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 108040007629 peroxidase activity proteins Proteins 0.000 description 16
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 16
- 238000001262 western blot Methods 0.000 description 16
- 102000016938 Catalase Human genes 0.000 description 15
- 108010053835 Catalase Proteins 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 238000003745 diagnosis Methods 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 14
- 230000005875 antibody response Effects 0.000 description 14
- 238000013459 approach Methods 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 229920002401 polyacrylamide Polymers 0.000 description 14
- 241001529936 Murinae Species 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 241000304886 Bacilli Species 0.000 description 12
- 230000001355 anti-mycobacterial effect Effects 0.000 description 12
- 239000003926 antimycobacterial agent Substances 0.000 description 12
- 210000002421 cell wall Anatomy 0.000 description 12
- 238000003119 immunoblot Methods 0.000 description 12
- 238000001179 sorption measurement Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 101710088427 Diacylglycerol acyltransferase/mycolyltransferase Ag85C Proteins 0.000 description 10
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 125000005647 linker group Chemical group 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 239000007790 solid phase Substances 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 101100509674 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) katG3 gene Proteins 0.000 description 9
- 239000000020 Nitrocellulose Substances 0.000 description 9
- 108010076039 Polyproteins Proteins 0.000 description 9
- 238000004422 calculation algorithm Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000013507 mapping Methods 0.000 description 9
- 229920001220 nitrocellulos Polymers 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 101150014428 mpt64 gene Proteins 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 230000000405 serological effect Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 239000003656 tris buffered saline Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 7
- 239000004793 Polystyrene Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 7
- 230000005750 disease progression Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 101710087887 Alkyl hydroperoxide reductase C Proteins 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000003435 aroyl group Chemical group 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000001155 isoelectric focusing Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 5
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 5
- 108010059013 Chaperonin 10 Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 125000001589 carboacyl group Chemical group 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 102000005396 glutamine synthetase Human genes 0.000 description 5
- 108020002326 glutamine synthetase Proteins 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 4
- 102100026189 Beta-galactosidase Human genes 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 108010058432 Chaperonin 60 Proteins 0.000 description 4
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 229920004929 Triton X-114 Polymers 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 4
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000032420 Latent Infection Diseases 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000187480 Mycobacterium smegmatis Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000721 bacterilogical effect Effects 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 101150116082 glcB gene Proteins 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000000984 immunochemical effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000011005 laboratory method Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 229940023041 peptide vaccine Drugs 0.000 description 3
- 235000020030 perry Nutrition 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 101710127328 28 kDa antigen Proteins 0.000 description 2
- 101150117081 51 gene Proteins 0.000 description 2
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 101000609447 Beet necrotic yellow vein virus (isolate Japan/S) Protein P25 Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 101710087104 Invasin IpaC Proteins 0.000 description 2
- 101001060713 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) Flagellar filament 35 kDa core protein Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108020004687 Malate Synthase Proteins 0.000 description 2
- 101710164418 Movement protein TGB2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 101001013152 Mycobacterium avium Major membrane protein 1 Proteins 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- 101001013151 Mycobacterium leprae (strain TN) Major membrane protein I Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 206010051738 Pulmonary cavitation Diseases 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 101000980867 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Curved DNA-binding protein Proteins 0.000 description 2
- 101000982319 Shallot virus X Uncharacterized ORF4 protein Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101000913850 Tetrahymena thermophila Citrate synthase, mitochondrial Proteins 0.000 description 2
- 101000638142 Treponema pallidum (strain Nichols) Membrane lipoprotein TmpC Proteins 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 238000007818 agglutination assay Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 238000003277 amino acid sequence analysis Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 229940025131 amylases Drugs 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000004970 cd4 cell Anatomy 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 101150020570 fbpC gene Proteins 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002169 hydrotherapy Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 102000028557 immunoglobulin binding proteins Human genes 0.000 description 2
- 108091009323 immunoglobulin binding proteins Proteins 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000009117 preventive therapy Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940023143 protein vaccine Drugs 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- KHNDABJZSPPYLE-FUGFVFQCSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[2-[[(3s,5r,8r,9s,10s,12r,13s,14s,17r)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]acetyl]amino]hexanoate Chemical compound O([C@@H]1C[C@H]2CC[C@H]3[C@@]4(O)CC[C@@H]([C@]4([C@@H](C[C@@H]3[C@@]2(C)CC1)O)C)C=1COC(=O)C=1)CC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O KHNDABJZSPPYLE-FUGFVFQCSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZLUSTGDGOTYUPV-DKWTVANSSA-N (2s)-2-aminopropanoic acid;propane-1,2,3-triol Chemical class C[C@H](N)C(O)=O.OCC(O)CO ZLUSTGDGOTYUPV-DKWTVANSSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 101710097814 13 kDa protein Proteins 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- NDTDVKKGYBULHF-UHFFFAOYSA-N 2-(1-hydroxy-3-phenylnaphthalen-2-yl)-3-phenylnaphthalen-1-ol Chemical compound C=1C2=CC=CC=C2C(O)=C(C=2C(=CC3=CC=CC=C3C=2O)C=2C=CC=CC=2)C=1C1=CC=CC=C1 NDTDVKKGYBULHF-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- PHLXSNIEQIKENK-UHFFFAOYSA-N 2-[[2-[5-methyl-3-(trifluoromethyl)pyrazol-1-yl]acetyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound CC1=CC(C(F)(F)F)=NN1CC(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 PHLXSNIEQIKENK-UHFFFAOYSA-N 0.000 description 1
- 125000006197 2-benzoyl ethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(=O)C([H])([H])C([H])([H])* 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- XDWXDKYBDCMXLC-UHFFFAOYSA-N 4-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]naphthalen-1-ol Chemical compound C1=CC=C2C(OCCOCCOCCO)=CC=C(O)C2=C1 XDWXDKYBDCMXLC-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 101710122462 65 kDa protein Proteins 0.000 description 1
- BOBBYBHJYYJHHQ-UHFFFAOYSA-N 7-tert-butyl-6-(4-chlorophenyl)-2-sulfanylidene-1h-pyrido[2,3-d]pyrimidin-4-one Chemical compound CC(C)(C)C1=NC=2NC(=S)NC(=O)C=2C=C1C1=CC=C(Cl)C=C1 BOBBYBHJYYJHHQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 108010031025 Alanine Dehydrogenase Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 101100450144 Arabidopsis thaliana HAT3 gene Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 101001057129 Bacillus cereus Enterotoxin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000008001 CAPS buffer Substances 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241001267419 Eubacterium sp. Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010000916 Fimbriae Proteins Proteins 0.000 description 1
- 241000192016 Finegoldia magna Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102100021467 Histone acetyltransferase type B catalytic subunit Human genes 0.000 description 1
- 101000898976 Homo sapiens Histone acetyltransferase type B catalytic subunit Proteins 0.000 description 1
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100024067 Inhibitor of growth protein 2 Human genes 0.000 description 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000006391 Luria-Bertani Medium Substances 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000545499 Mycobacterium avium-intracellulare Species 0.000 description 1
- 101100291912 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) mpb64 gene Proteins 0.000 description 1
- 101100131080 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) mpb70 gene Proteins 0.000 description 1
- 101000700655 Mycobacterium leprae (strain TN) Serine-rich antigen Proteins 0.000 description 1
- 101001043272 Mycobacterium tuberculosis (strain ATCC 25177 / H37Ra) Lipoprotein LpqH Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 101000793655 Oryza sativa subsp. japonica Calreticulin Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 description 1
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 101710151911 Phosphoprotein p30 Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 101100230601 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HBT1 gene Proteins 0.000 description 1
- 229940124842 Salmonella vaccine Drugs 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100021225 Serine hydroxymethyltransferase, cytosolic Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 101001009612 Toxoplasma gondii Dense granule protein 6 Proteins 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005082 alkoxyalkenyl group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000005021 aminoalkenyl group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000005014 aminoalkynyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000776 antibody secreting cell Anatomy 0.000 description 1
- 101150080488 apa gene Proteins 0.000 description 1
- 125000006196 aroyl alkyl group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000005019 carboxyalkenyl group Chemical group 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000003115 checkerboard titration Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 150000003972 cyclic carboxylic anhydrides Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000026502 entry into host cell Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 101150028082 fbpA gene Proteins 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 102000036072 fibronectin binding proteins Human genes 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JORABGDXCIBAFL-UHFFFAOYSA-M iodonitrotetrazolium chloride Chemical compound [Cl-].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C=CC=CC=2)=N1 JORABGDXCIBAFL-UHFFFAOYSA-M 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052622 kaolinite Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000005358 mercaptoalkyl group Chemical group 0.000 description 1
- RMAHPRNLQIRHIJ-UHFFFAOYSA-N methyl carbamimidate Chemical compound COC(N)=N RMAHPRNLQIRHIJ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000004196 psta Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000012124 rapid diagnostic test Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000002922 simulated annealing Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Definitions
- the invention in the fields of microbiology and medicine relates to methods for rapid early detection of mycobacterial disease in humans based on the presence of antibodies to particular "early" mycobacterial protein antigens, and reactive epitopes thereof, which have not been previously recognized for this purpose.
- Assay of such antibodies on selected mycobacterial proteins, peptides thereof, or fusion polypeptides (peptide multimers, polyproteins) permits diagnosis of TB earlier than has been heretofore possible.
- a surrogate marker for screening populations at risk for TB in particular subjects infected with human immunodeficiency virus (HIN).
- HIN human immunodeficiency virus
- M. tuberculosis Mycobacterium tuberculosis
- Mtb Mycobacterium tuberculosis
- High risk populations are also found in the United States, primarily intravenous drug users, homeless people, prison inmates and residents of slum areas (Fitzgerald, IM et al, 1991, Chest 100:191-200; Graham et al, supra; Friedman, L ⁇ et al, 1996, New Engl J. Med. 334:828-833) as well as household contacts of TB patients.
- discovery of additional surrogate markers for early detection and prompt treatment of active, subclinical TB in such high risk populations is urgently required.
- Antibody responses in TB have been studied for several decades primarily for the purpose of developing serodiagnostic assays. Although some seroreactive antigens/epitopes have been identified, interest in antibody responses to Mtb has waned because of the lack of progress in simple detection of corresponding antibodies. Studies using crude antigen preparations revealed that healthy individuals possess antibodies that cross-react with several mycobacterial antigens presumably elicited by exposure to commensal and environmental bacteria and vaccinations (Bardana, EJ et al, 1973, Clin. Exp. Immunol. 13:65-11; Das, S et al, 1992, Clin. Exp. Immunol.
- MPB denotes a protein purified from M. bovis BCG followed by a number denoting its relative mobility in 7.7% polyacrylamide gels at a pH of 9.5.
- MPT denotes a protein isolated from Mtb.
- Mtb proteins which include a complex of 3 proteins termed antigens 85 A, 85B and 85C (also known as the "85 complex” or "85cx") (Wiker, H.G. et al, 1992, Scand. J. Immunol. 36:301-319; Wiker, H.G. et al, 1992, Microbiol. Rev. 56:648-661).
- the corresponding components of Mtb are also actively secreted.
- the 85 complex is considered the major secreted protein constituent of mycobacterial culture fluids though it is also found in association with the bacterial surface. In most SDS- polyacrylamide gel electrophoresis (SDS-PAGE) analyses, 85A and 85C are not properly resolved, whereas isoelectric focusing resolves three distinct bands.
- EIA enzyme immunoassay
- the N-terminal sequence of MPT51 showed 72% homology with the sequence of the Ag 85 components (when P at position 2 is aligned with P at position 7 of the three Ag 85 components.
- Studies of TB patients showed that assays of antibodies to the Ag 85 complex had a sensitivity of about 50%.
- the Ag 85 components are highly cross- reactive so that positive responses are expected (and found) in healthy controls, particularly in geographic areas of high exposure to atypical mycobacteria. The different degree of specificity is thus highly dependent on the kind of control subjects used. It is noteworthy that traditional BCG vaccination does not appear to induce a significant antibody response, though it is interesting that antibodies to mycobacterial antigens increased when anti-TB chemotherapy was initiated.
- Mtb 50/55 kDa antigen secreted glycoproteins.
- the ⁇ -terminal sequences and total amino acid content of these proteins were very similar. 2D gel electrophoresis showed at least seven different components in the Mtb 50/55 kDa antigen.
- the ⁇ -terminus of the Mtb Al kDa antigen known as MPT32 was very similar to the ⁇ -termini of the 50/55 kDa - and the 45-47 kDa proteins. The authors speculated about a diagnostic potential for these antigens based on these observation However, the potential of this antigen as an early diagnostic agent for TB was neither analyzed nor even suggested.
- Urnovitz HB et al (Lancet Dec 11 1993, 342:1458-9), discovered that 7 individuals who were negative for HIV-1 antibody in a licensed serum EIA were positive in a urine EIA and western blot (WB).
- Connell JA et al JMed Virol 1993, 41:159-64, described a rapid, simple, and robust IgG-capture enzyme-linked immunosorbent assay (GACELISA) suitable for the detection of anti-HJN 1 and 2 antibodies in saliva and urine.
- GACELISA IgG-capture enzyme-linked immunosorbent assay
- HBs hepatitis B surface antigen
- HBc hepatitis B core antigen
- CMN CMN and HTV
- HBs hepatitis B surface antigen
- HBc hepatitis B core antigen
- CMN CMN and HTV
- the present inventors have systematically analyzed the reactivity of sera and urine from TB patients with antigens from Mtb to delineate the major targets of human antibody responses which occur relatively early in the progression of the infection to disease. They observed that initial immunoadsorption of patient sera with E. coli antigens successfully reduced interference by cross-reactive antibodies, thus allowing a new approach to serological studies.
- the immunoadsorbed sera allowed identification of a number of antigens of Mtb that are recognized by antibodies in a large proportion of patients, and during earlier stages of disease progression. These antigens are therefore useful tools in methods of diagnosing TB.
- Prominent among these antigens is a high molecular weight secreted protein of 88kDa or 85kDa (depending on conditions as will be described below). This protein is termed “the 88 kDa protein” and, as discovered later, as the product of the glcB gene, is also termed GlcB (see below).
- the present invention In addition to its utility for early diagnosis of mycobacterial disease in a subject prior to the development of radiographic or bacteriological evidence of the disease, the present invention also provides for the first time a surrogate marker that can be used in an inexpensive screening method in individuals at heightened risk for developing TB.
- This utility was discovered by applying the approach described herein to analyze antibody responses of HTV-infected TB patients (HIN/TB) to the secreted antigens of Mtb during different stages of disease progression.
- HIN/TB HTV-infected TB patients
- a majority of the HIN/TB patients had detectable antibodies to the secreted antigens of Mtb for months, even years, prior to the clinical manifestation of active tuberculous disease. These patients are termed "HTV/pre-TB".
- HIN/TB patients compared to the TB patients not infected with HIN (designated "non-HIN/TB"), HIN/TB patients had significantly lower levels of antibodies which showed specificity for a restricted repertoire of Mtb antigens.
- Antibodies to the 88 kDa antigen mentioned above were present in about 75% of the HIN/pre-TB sera patients who eventually developed clinical TB. HIV/TB patients who failed to develop anti- t ⁇ antibodies did not differ in their lymphocyte profiles from those that were antibody-positive.
- the present invention is directed to an antigenic composition useful for early detection of M. tuberculosis disease or infection or for immunizing a subject against M. tuberculosis infection, comprising
- ELA APDEIREEVDNNC (SEQ ID NO: 110); (4) HRRRREFKARAAEKPAPSDRAG (SEQ ID NO: 111); (5) ARDELQAQIDK HRRR (SEQ ID NO: 112); (6) LNRDRNYTAPGGGQ (SEQ ID NO: 113); (7) GAPQLGRWKWHDPWV (SEQ ID NO: 114) (8) VGNLRIARVLYDF (SEQ ID NO: 117); (9) QAQIDKWHRRRVI (SEQ ID NO: 126); (10) WHRRRVIEPIDMD (SEQ ID NO: 127); (11)
- IEPIDMDAYRQFL (SEQ ID NO: 128); (12) ITTTAGPQLVVPV (SEQ ID NO:134); (13) PQLVVPVLNARFA (SEQ ID NO:135); (14) VLNARFALNAANA (SEQ ID NO: 136); (15) ALNAANARWGSLY (SEQ ID NO: 137); (16) AR GSLYDALYGT (SEQ ID 0:138); (17) SVLLINHGLHIEI (SEQ ID NO: 154); (18) HGLHIEILIDPES (SEQ ID NO: 155); (19) GGQFTLPGRSLMF
- composition is not the full length protein having the sequence SEQ ID NO: 106 or SEQ ID NO: 107;
- the above antigenic composition is a fusion polypeptide that includes: (a) one or more of the peptides (l)-(23) or the variants, linked to (b) one or more proteins selected from the group consisting of SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO: 106, SEQ ID NO:
- an antigenic composition as above which is:
- peptide multimer reacts with an antibody specific for the GlcB or MPT51 protein.
- the invention is also directed to an antigenic composition as above which is a recombinant peptide multimer having the formula:
- P 1 and P 2 may be the same or different and each occurrence of P x in the 1 -Gly 2 structure may be a different peptide or variant from its adjacent neighbor;
- An antigenic composition useful for early detection of M. tuberculosis disease or infection may comprise one or more peptides in a mixture or linked in a peptide multimer or fusion protein, which one or more peptides are derived from or have a sequence corresponding to a fragment of an early M. tuberculosis antigen which antigen is characterized as being (i) reactive with antibodies found in tuberculosis patients who are in a stage of disease prior to the onset of sputum smear-positivity and cavitary pulmonary lesions, and
- a preferred method for the early detection of mycobacterial disease or infection in a subject comprises assaying a biological fluid sample from a subject suspected of having active TB for the presence of antibodies specific for the above peptide or variant, fusion protein or peptide multimer, wherein the presence of the antibodies is indicative of the presence of the disease or infection.
- the biological fluid sample is preferably taken from a subject having symptoms of active tuberculosis, but before the onset of symptoms identifiable as advanced tuberculosis that is distinguished by (a) smear positivity of sputum or other pulmonary associated fluid for acid-fast bacilli, (b) cavitary puhnonary lesions, or both (a) and (b).
- the method includes, before the assaying, the step of obtaining the biological fluid sample from the subject
- the above method preferably includes, prior to the assaying step, removing from the sample antibodies specific for cross-reactive epitopes or antigens between proteins present in M. tuberculosis and in other bacterial genera, for example, by immunoadsorption of the sample with
- the above method may further comprise assaying the sample for the presence of antibodies specific for one or more additional early antigens of M. tuberculosis selected from the group consisting of:
- the preferred subject in the above methods is a human, such as human infected with HIV-1 or at high risk for tuberculosis.
- the biological fluid sample is serum, urine or saliva.
- the method may further include performance of a test that detects mycobacterial bacilli in a sample of sputum or other body fluid of the subject.
- the invention is also directed to a kit useful for early detection of M. tuberculosis disease, the kit comprising:
- the kit may also comprise one or more early antigens of M. tuberculosis, for example, an antigens is selected from the group consisting of:
- Figure 1 shows the reactivity of sera from TB neg HTV neg PPD + controls( O ); TB neg HTV nes
- LAM-free culture filtrate proteins (LFCFP) of Mtb H Rv, before and after adsorption with E. coli lysate. Values are individuals OD's with the mean shown as a horizontal bar.
- Figure 2 shows reactivity of sera from non-HIN, PPD skin test positive (PPD + ) healthy controls (non-HIN/PPD), non-HIN TB patients (non-HIN/TB) and HIN-infected TB patients (HIN/pre-TB, HIN/at-TB and HIN/post-TB) with total LFCFP of Mtb.
- the cut-off was determined by the mean optical density (OD) ⁇ 3 standard deviations, obtained with the healthy control sera.
- Figure 3 is a graph showing reactivity of sera from advanced (black bars) and early (gray bars) TB patients to M. tuberculosis LFCFP, purified Ag85C or three fractions (13, 10 and 15) enriched for three early antigens (shown in parentheses below the fraction designation).
- Figure 4 is a graph showing reactivity of sera from advanced (black bars) and early (gray bars) TB patients to Mtb LFCFP, purified Ag85C or purified MPT32.
- Figure 5 is a graph showing reactivity of urine and sera from late TB patients with LFCF and MP32 protein. Results are presented as percent samples that are positive.
- the present invention provides a diagnostic immunoassay method to detect and/or quantitate antibodies specific for mycobacterial antigens, in particular, antibodies developing early in the progression of M. tuberculosis infection to disease and before clinical manifestations of that disease.
- the best antigen available prior to this invention for serodiagnosis of TB was the 38 kDa secreted protein also known as Ag 78 (see above).
- the present invention permits detection of serological reactivity in subject who lack detectable antibodies to this 38 kDa antigen.
- the immunoassay method is based upon the present inventors' discovery that certain Mtb antigens induce in humans an earlier response than do other antigens which elicit antibodies only after the disease is already clinically advanced. In HIN-infected subjects with dysfunctional immune systems, antibodies to some of these antigens are detectable long before TB is clinically manifest. Five secreted proteins have been identified as early antigens with diagnostic value.
- a preferred early antigen is a 88kDa secreted protein of Mtb GlcB, preferably enriched or semipurified (at least 50% pure) or highly purified (at least 95% pure, preferably at least 99% pure).
- epitope-bearing peptides from GlcB and from MPT51 that are reactive with TB sera and which are used in early diagnosis in the form of peptides (single peptide or mixtures), peptide multimers (synthetic or recombinant) comprising one or more different epitope-bearing peptides, or fusion polyproteins that comprise at least two full length early antigen proteins and may include additional epitopes based on peptides of the same or other Mtb proteins.
- the present method is further based on the inventors' conception of the importance of first removing antibodies specific for cross-reactive antigens (which are not Mtb-specific) prior to analyzing the antigenic reactivity and specificity of serum from patients infected with Mtb on crude or semipurified antigenic preparations.
- purified antigens are provided or epitope-specific competitive EIAs are established based on this invention (see, for example, Wilkins, E. et al, 1991, Eur. J. Clin. Microbiol. Infect. Dis. 20:559-563)
- the need for such prior absorption steps should be obviated.
- Mtb infection or disease or the subject having the infection or disease, (2) the antibody response to an Mtb antigen, (3) an Mtb antigen itself or (4) a diagnostic assay, are defined in terms of the stage of development of TB. Early and late (or advanced) TB are defined in the table below.
- a subject with early TB is asymptomatic or, more typically, has one or more "constitutional symptoms" (e.g., fever, cough, weight loss), hi early TB, Mtb bacilli are too few to be detectable as acid-fast bacilli in smears of sputum or other body fluid, primarily those fluids associated with the lungs (such as bronchial washings, bronchoalveolar lavage, pleural effusion). However, in these subjects, Mtb bacilli are present and culturable, i.e., can be grown in culture from the above body fluids. Finally, early TB subjects may have radiographically evident pulmonary lesions which may include infiltration but without cavitation.
- substitutional symptoms e.g., fever, cough, weight loss
- Mtb bacilli are too few to be detectable as acid-fast bacilli in smears of sputum or other body fluid, primarily those fluids associated with the lungs (such as
- any antibody present in such early stages is termed an “early antibody” and any Mtb antigen recognized by such antibodies is termed an “early antigen.”
- an antibody is characterized as “early” does not mean that this antibody is absent in advanced TB. Rather, such antibodies are expected to persist across the progression of early TB to the advanced stage.
- the term “late” or “advanced” is characterized in that the subject has frank clinical disease and more advanced cavitary lesions in the lungs, h late TB, Mtb bacilli are not only culturable from smears of sputum and/or the other body fluids noted above, but also present in sufficient numbers to be detectable as acid-fast bacilli in smears of these fluids.
- an antibody that first appears after the onset of diagnostic clinical and other characterizing symptoms is a late antibody, and an antigen recognized by a late antibody (but not by an early antibody) is a late antigen.
- an early diagnostic assay must permit rapid diagnosis of Mtb disease at a stage earlier than that which could have been diagnosed by conventional clinical diagnostic methods, namely, by radiologic examination and bacterial smear and culture or by other laboratory methods available prior to this invention.
- the present immunoassay typically comprises incubating a biological fluid, preferably serum or urine , from a subject suspected of having TB, in the presence of an Mtb antigen- containing reagent which includes one or more Mtb early antigens. They may be combined as mixtures or as polyproteins or peptide multimers based on units of epitope-bearing peptide. The binding of antibodies in the sample to the mycobacterial antigen(s) is then detected.
- biological fluid any fluid derived from the body of a normal or diseased subject which may contain antibodies, such as blood, serum, plasma, lymph, urine, saliva, sputum, tears, cerebrospinal fluid, bronchioalveolar lavage fluid, pleural fluid, bile, ascites fluid, pus and the like. Also included within the meaning of this term as used herein is a tissue extract, or the culture fluid in which cells or tissue from the subject have been incubated.
- the mycobacterial antigenic composition or preparation of the present invention maybe one or a combination of isolated proteins or peptides of aM tuberculosis secreted protein. As stated above, the combination may be produced as a mixture or as a polyprotein or peptide multimer.
- the antigen composition may be a substantially purified or recombinantly produced preparation of one or more M. tuberculosis proteins or epitope-bearing peptides thereof.
- the antigen composition may be a partially purified or substantially pure preparation containing one or more M tuberculosis epitopes which are capable of being bound by antibodies of a subject with TB. Such epitopes may be in the form of peptide fragments of the early antigen proteins or other "functional derivatives" of M. tuberculosis proteins or peptides as described below.
- a functional derivative is meant a “fragment,” “variant,” “analogue,” or “chemical derivative” of an early antigen protein, which terms are defined below.
- a functional derivative retains at least a portion of the function of the protein which permits its utility in accordance with the present invention - primarily the capacity to bind to an early antibody.
- a “fragment” refers to any subset of the molecule, that is, a shorter peptide.
- a “variant” refers to a molecule substantially similar to either the entire protein or fragment thereof.
- a variant peptide may be conveniently prepared by direct chemical synthesis or by recombinant means.
- a "chemical derivative” of the antigenic protein or peptide contains additional chemical moieties not normally part of the native protein (or of a peptide fragment).
- Covalent modifications of the peptide are included within the scope of this invention. Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues.
- Mtb proteins or glycoproteins, identified in culture filtrates of Mtb, are the preferred early Mtb antigens (or sources of antigenic peptides) of the present invention. Thus, although these proteins are considered to be secreted proteins, they may also be present in cellular preparations of the bacilli. Thus, these early antigens are not intended to be limited to the secreted protein form.
- the proteins are characterized as follows: (1) 88 kDa protein (GlcB)
- This protein was discovered by the present inventors as an Mtb secreted protein having a molecular mass of 88 kDa and an isoelectric point of about pH 5.2 when isolated from the culture filtrate. This protein migrated at a molecular mass range of 82 - 85 kDa in one co- inventor's laboratory (or 88kDa in another co-inventor's laboratory) and a pi range of 5.12 - 5.19. This protein was originally thought to react with both mAb IT-42 and mAb IT-57, but it was later found that a second proteins in this MW range, the catalase/peroxidase (katG gene producfjwas reactive with those mAbs.
- Th 88 kDa protein is a major antigenic component of Fraction 15 (Example I) and Fraction 14 (Example U).
- This protein corresponds to the protein spot designated Ref. No. 124 in 2D gels now shown here (see US Patent 6,245,331 and WO 98/29132 (published 09 July 1998) both incorporated by reference in their entirety; see also Tables 4 and 6, below).
- a single protein is intended (although different isoforms may be found to exist).
- Example IN the sequence of this protein was identified by the present inventors based on amino acid composition in relation to the Mtb genomic sequence obtained after the filing date of the present inventors' priority application Serial No. US 60/034,003, filed 31 December 1996.
- This protein is the product of the Mtb glcB gene which encodes the malate synthase enzyme and is termed the GlcB protein.
- This protein has the amino acid sequence (SEQ ID NO: 106) as shown below:
- Mtb ⁇ l which they concluded may be useful for the diagnosis of TB, especially for patients coinfected with HIN.
- Recombinant Mtb81 tested by ELISA detected antibodies in 25/27 TB patients (92%) seropositive for HIN as well as in 38/67 individuals (57%) who were TB positive alone.
- Antigen 85C This is an Mtb secreted protein having an apparent molecular weight of about 31 kDa and an isoelectric point of about pH 5.17. This protein is reactive with mAb IT-49 and has also been designated MPT45. Ag85C corresponds to the protein spot designated Ref. No. 119 in Table 4 or Table 6.
- MPT51 Mtb secreted protein having an apparent molecular weight of about 31 kDa and an isoelectric point of about pH 5.17. This protein is reactive with mAb IT-49 and has also been designated MPT45. Ag85C corresponds to the protein spot designated Ref. No. 119 in Table 4 or Table 6.
- This Mtb secreted protein has an apparent molecular mass of about 27kDa and an isoelectric point of about 5.91 and the amino acid sequence SEQ ID NO:107.
- GenBank sequence includes the full length gene so that the amino acid sequence includes a 33 residue signal sequence that is cleaved from the protein before it is secreted.
- the final protein product is SEQ ID NO:107 as shown.
- MPT51 is reactive with mAb IT-52. This protein corresponds to the protein spot designated Ref. No. 170 in 2D gels not shown here (summarized in Table 4 and Table 6).
- This glycoprotein has an apparent molecular mass (as a doublet peak) of 38 and 42 kDa (42/45 kDa according to Espitia et al.(supra)) and an isoelectric point of about pH 4.51. It is reactive with a polyclonal anti-MPT 32 antiserum. This protein is a major antigenic component of Fraction 13 (see Examples). MPT32 corresponds to the protein spot designated Ref. No. 14 in Table 4 or Table 6.
- 49 kDa protein One additional protein, termed the “49 kDa protein,” has an apparent molecular mass of about 49 kDa and an isoelectric point of about pH 5.1. This protein reacts with mAb IT-58 and corresponds to a spot identified as Ref. No. 82 in Table 4 or Table 6.
- the present invention also provides peptides of GlcB and of MPT51, early antigenic Mtb proteins. Such peptides are also useful as diagnostic and vaccine compositions. As shown in Examples IX, preferred peptides that were predicted and indeed shown to react with TB sera include, but are not limited to
- GAPQLGRWKWHDPWV which corresponds to MPT51 residues 167-181 (SEQ ID NO: 114);
- LRIARVLYDF (SEQ ID NO: 117); (9) QAQIDKWHRRRNI (SEQ ID NO: 126); (10) WHRRRVIEPIDMD (SEQ ID NO: 127);
- ARWGSLYDALYGT SEQ ID NO: 138
- FVRNVGHLMTNDA (SEQ ID NO: 172); (21) DRWFTNTGFLDR (SEQ ID NO: 191);
- a peptide which includes an antibody epitopes should have at least about 5 amino acids.
- a T cell epitope is preferably between about 10 and 15 amino acids.
- the present invention includes peptides having between about 5 and 30 residues, having the native sequences of the Mtb early antigenic proteins or being homologues, substitution variants, addition variants or deletion variants thereof.
- the peptide When the peptide is to be administered to a subject, particularly for the vaccine embodiments of this invention, the peptide may be capped at its N and C termini with an acyl (abbreviated “Ac”) -and an amido (abbreviated “Am”) group, respectively, for example acetyl (CH 3 CO-) at the N terminus and amido (-NH 2 ) at the C terminus.
- Ac acyl
- Am amido
- N-terminal capping functions preferably in a linkage to the tenninal amino group, is contemplated, for example: formyl; alkanoyl, having from 1 to 10 carbon atoms, such as acetyl, propionyl, butyryl; alkenoyl, having from 1 to 10 carbon atoms, such as hex-3-enoyl; alkynoyl, having from 1 to 10 carbon atoms, such as hex-5-ynoyl; aroyl, such as benzoyl or 1-naphthoyl; heteroaroyl, such as 3-pyrroyl or 4-quinoloyl; alkylsulfonyl, such as methanesulfonyl; arylsulfonyl, such as benzenesulfonyl or sulfanilyl; heteroarylsulfonyl, such as pyridine-4-sulfonyl; substituted alkanoyl
- the C-terminal capping function can either be in an amide or ester bond with the terminal carboxyl.
- Capping functions that provide for an amide bond are designated as NR R 2 wherein R and R may be independently drawn from the following group: hydrogen; alkyl, preferably having from 1 to 10 carbon atoms, such as methyl, ethyl, isopropyl; alkenyl, preferably having from 1 to 10 carbon atoms, such as prop-2-enyl; alkynyl, preferably having from 1 to 10 carbon atoms, such as prop-2-ynyl; substituted alkyl having from 1 to 10 carbon atoms, such as hydroxyalkyl, alkoxyalkyl, mercaptoalkyl, alkylthioalkyl, halogenoalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkanoylalkyl, carboxyalkyl, carbamoylal
- Capping functions that provide for an ester bond are designated as OR, wherein R may be: alkoxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; substituted alkoxy; substituted aryloxy; substituted heteroaryloxy; substituted aralkyloxy; or substituted heteroaralkyloxy.
- the peptides of the invention may be prepared using recombinant DNA technology. However, some of the shorter peptides may be prepared using solid-phase synthesis, such as that generally described by Merrifield, J. Amer. Chem. Soc, 55:2149-54 (1963), although other equivalent chemical syntheses known in the art are also useful. Solid-phase peptide synthesis may be initiated from the C-terminus of the peptide by coupling a protected ⁇ -amino acid to a suitable resin.
- Such a starting material can be prepared by attaching an ⁇ -amino-protected amino acid by an ester linkage to a chloromethylated resin or to a hydroxymethyl resin, or by an amide bond to a BHA resin or MBHA resin.
- Such methods well-known in the art, are disclosed, for example, in U.S. 5,994,309 (issued 11/30/1999) which is incorporated by reference in its entirety.
- peptides in which at least one amino acid residue and preferably, only one, has been removed and a different residue inserted in its place compared to the native Mtb sequence.
- the types of substitutions which maybe made in the peptide molecule of the present invention are conservative substitutions, which are typically exchanges within one of the following groups: 1. Small aliphatic, nonpolar or slightly polar residues: e.g. , Ala, Ser, Thr, Gly;
- Polar, negatively charged residues and their amides e.g., Asp, Asn, Glu, Gin;
- Polar, positively charged residues e.g., His, Arg, Lys;
- substitutions that are less conservative, such as between, rather than within, the above groups (or two other amino acid groups not shown above), which will differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
- Preferred substitutions according to the present invention are those that do not produce radical changes in the characteristics of the peptide molecule.
- Addition variants of the present Mtb peptides preferably include from 1-4 amino acids, but may include as many as X amino acids, added either at the N-terminus, the C-terminus or both.
- Amino acids that are added to the basic peptide unit are ones that permit the peptide to maintain its biological reactivity in accordance with this invention, namely antigenicity (recognition by antibodies or T lymphocytes) or immunogenicity in the case of vaccine embodiments.
- preferred variants are those that have increased stability and/or immunogenicity.
- stability is increased by introducing one or more Cys residues into strategic positions , where the formation of disulfide bonds between two Cys residues increases stability.
- Another approach is based on introduction of residues that form ⁇ helices at sites that do not impede the peptide immunologic activity, for example at the N- and C- termini.
- n residues as many as (n-5) amino acids ' maybe substituted, provided that the characteristic immunoreactivity with early Mtb antibodies is not lost.
- Lysinyl and amino terminal residues may be derivatized with succinic or other carboxylic acid anhydrides. Derivatization with a cyclic carboxylic anhydride has the effect of reversing the charge of the lysinyl residues.
- Other suitable reagents for derivatizing ⁇ -amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.
- aspartyl and glutamyl residues can be converted to asparaginyl and glutaminyl residues by reaction with ammonia.
- the present invention also includes longer peptides or polypeptides in which a sequence of an Mtb early antigenic peptide or a substitution or addition variant thereof, or a chemical derivative thereof, is repeated from two to about 100 times, with or without intervening spacers or linkers.
- Such molecules are termed in the art, interchangeably, multimers, concatemers or multiepitope polyproteins and will be referred to herein primarily as peptide multimers. When produced recombinantly, they are also considered to be fusion polypeptides or fusion proteins.
- peptide multimers may be built from any of the antigenic peptides or variants described herein.
- a peptide multimer may comprise different combinations of peptide monomers (either from the native sequence or variants thereof).
- a multimer may include several sequential repeats of a first peptide, followed by one or more repeats of a second peptide, etc.
- Such multimeric peptides can be made by chemical synthesis of individual peptides, recombinant DNA techniques or a combination, e.g., chemical linkage of recombinantly produced multimers.
- the multimers When produced by chemical synthesis, the multimers preferably have from 2-12 repeats, more preferably 2-8 repeats of the core peptide sequence, and the total number of amino acids in the multimer should not exceed about 110 residues (or their equivalents, when including linkers or spacers).
- a preferred synthetic chemical peptide multimer has the formula
- a preferred synthetic chemical peptide multimer has the formula
- P and P 2 are Mtb peptides or addition variants of these peptides, wherein
- P 1 and P 2 may be the same or different; moreover, each occurrence of P 1 in the multimer may be a different peptide (or variant) from its adjacent neighbor;
- a preferred recombinantly produced peptide multimer has the formula:
- P and P is preferably selected from any one of the followings SEQ ID NO's: 108- 114; 117;126-128, 134-138, 154, 155, 170, 172, 191, 216, and 217.
- the multimer is optionally capped at its N- and C-termini
- multimers may be built from any of the peptides or variants described herein. Although it is preferred that the addition variant monomeric units of the multimer have the biological activity described above, that is not necessary as long as the multimer to which they contribute has the activity.
- the present invention includes as fusion polypeptide which may comprise a linear multimer of two or more repeats of the above peptide monomers linked end to end, directly or with a linker sequences present between the monomer repeats and further fused to another polypeptide sequence which permits or enhances the activity of the antigenic peptides in accordance with this invention.
- the present multimers and fusion polypeptides may therefore include more than one epitope from the same or different Mtb proteins that do not occur together, i.e., in a contiguous structure, in a native Mtb protein.
- polyproteins or fusion proteins which combine longer polypeptides, even full length Mtb proteins such as GlcB, MPT51 and other Mtb early antigens described herein in various combinations, such as a fusion of GlcB and MPT51 or these two with another one or more early antigenic protein.
- Mtb proteins such as GlcB, MPT51 and other Mtb early antigens described herein in various combinations, such as a fusion of GlcB and MPT51 or these two with another one or more early antigenic protein.
- These full length proteins may be combined in polyproteins with shorter epitope-bearing Mtb peptides or variants thereof or with peptide multimers (homo- or heteromultimers.
- Such fusion proteins optionally includes spacers or linkers between some or all of the individual protein or peptide units.
- Peptides and multimers may be chemically conjugated to form multimers and larger aggregates.
- Preferred conjugated multimers include Cys and are made by forming disulfide bonds between the -SH groups of these residues, resulting in branched chains as well as straight chain peptides or polypeptides.
- the present multimers and fusion polypeptides may include linkers that are cleavable by an enzyme.
- Preferred enzymes are a matrix metalloprotealse, urokinase, a cathepsin, plasmin or thrombin.
- a preferred linker is a peptide having the sequence VPRGSD (SEQ ID NO:l 15) or DDKDWH (SEQ ID NO:238).
- peptides may be combined in the form of fusion polypeptides that comprise one or more repeats of a single peptide or mixtures of such peptides fused to other proteins, e.g., carrier molecules or other proteins which would enhance their immunogenicity when used as vaccine compositions.
- Additional compositions within the scope of this invention are the foregoing peptides, multimers or fusion polypeptides immobilized to a solid support or carrier for use in immunoassays.
- solid phase support is intended any support capable of binding antigen or antibodies.
- Supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, polyvinylidene difluoride, agaroses such as Sepharose®, and magnetic beads.
- the support material may have virtually any possible structural configuration so long as the immobilized peptide or polypeptide is capable of binding to its target molecule, e.g., antibody.
- the support configuration can include microparticles, beads, porous and impermeable strips and membranes, the interior surface of a reaction vessel such as a test tube or a microtiter plate, the external surface of a rod, and the like.
- a reaction vessel such as a test tube or a microtiter plate
- the external surface of a rod and the like.
- kits of the present invention may include one or more of the various peptide compositions described herein.
- the mycobacterial antigen composition is brought in contact with, and allowed to bind to, a solid support or carrier, such as nitrocellulose or polystyrene, allowing the antigen composition to adsorb and become immobilized to the solid support.
- a solid support or carrier such as nitrocellulose or polystyrene
- This immobilized antigen is then allowed to interact with the biological fluid sample which is being tested for the presence of anti-Mtb antibodies, such that any antibodies in the sample will bind to the immobilized antigen.
- the support to which the antibody is now bound may then be washed with suitable buffers after which a detectably labeled binding partner for the antibody is introduced.
- the binding partner binds to the immobilized antibody. Detection of the label is a measure of the immobilized antibody.
- a preferred binding partner for this assay is an anti-immunoglobulin antibody ("second antibody”) produced in a different species.
- second antibody an anti-immunoglobulin antibody
- a detectably labeled goat anti-human immunoglobulin "second” antibody may be used.
- the solid phase support may then be washed with the buffer a second time to remove unbound antibody.
- the amount of bound label on the solid support may then be detected by conventional means appropriate to the type of label used (see below).
- Such a “second antibody” maybe specific for epitopes characteristic of a particular human immunoglobulin isotype, for example IgM, IgG ⁇ IgG 2a , IgA and the like, thus permitting identification of the isotype or isotypes of antibodies in the sample which are specific for the mycobacterial antigen.
- the second antibody may be specific for an idiotype of the ant-Mtb antibody of the sample.
- binding partners for detection of the sample antibody other known binding partners for human immunoglobulins may be used.
- staphylococcal immunoglobulin binding proteins the best know of which is protein A.
- staphylococcal protein G or a recombinant fusion protein between protein A and protein G.
- Protein G (of group G and group C streptococci) binds to the Fc portion of Ig molecules as well as to IgG Fab fragment at the V H 3 domain.
- Protein C of Peptococcus magnus binds to the Fab region of the immunoglobulin molecule.
- Any other microbial immunoglobulin binding proteins for example from Streptococci, are also intended (for example, Langone, J. J., Adv. Immunol. 32:157 (1982)).
- a biological fluid suspected of containing antibodies specific for a Mtb antigen may be brought into contact with a solid support or carrier which is capable of immobilizing soluble proteins.
- the support may then be washed with suitable buffers followed by treatment with a mycobacterial antigen reagent, which may be detectably labeled. Bound antigen is then measured by measuring the immobilized detectable label. If the mycobacterial antigen reagent is not directly detectably labeled, a second reagent comprising a detectably labeled binding partner for the Mtb antigen, generally a second anti-Mtb antibody such as a murine mAb, is allowed to bind to any immobilized antigen.
- the solid phase support may then be washed with buffer a second time to remove unbound antibody. The amount of bound label on said solid support may then be detected by conventional means.
- solid phase support any support capable of binding a proteinaceous antigen or antibody molecules or other binding partners according to the present invention.
- supports, or carriers include glass, polystyrene, polypropylene, polyethylene, polyvinylidene difluoride, dextran, nylon, magnetic beads, amylases, natural and modified celluloses, polyacrylamides, agaroses, and magnetite.
- the nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.
- the support material may have virtually any possible structural configuration so long as it is capable of binding to an antigen or antibody.
- the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod.
- the surface may be flat such as a sheet, test strip, etc.
- Preferred supports include polystyrene beads, 96-well polystyrene microplates and test strips, all well-known in the art. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.
- a preferred type of immunoassay to detect an antibody specific for a mycobacterial antigen is an enzyme-linked immunosorbent assay (ELISA) or more generically termed an enzyme immunoassay (EIA).
- ELISA enzyme-linked immunosorbent assay
- EIA enzyme immunoassay
- a detectable label bound to either an antibody-binding or antigen-binding reagent is an enzyme. When exposed to its substrate, this enzyme will react in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or visual means.
- Enzymes which can be used to detectably label the reagents useful in the present invention include, but are not limited to, horseradish peroxidase, alkaline phosphatase, glucose oxidase, ⁇ -galactosidase, ribonuclease, urease, catalase, malate dehydrogenase, staphylococcal nuclease, asparaginase, ⁇ - 5-steroid isomerase, yeast alcohol dehydrogenase, ⁇ -glycerophosphate dehydrogenase, triose phosphate isomerase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.
- the detectable label may be a radiolabel, and the assay termed a radioimmunoassay (RIA), as is well known in the art. See, for example, Yalow, R. et al, Nature 184:1648 (1959); Work, T.S., et al, Laboratory Techniques and Biochemistry in Molecular Biology, North Holland Publishing Company, NY, 1978, incorporated by reference herein.
- the radioisotope can be detected by a gamma counter, a scintillation counter or by autoradiography. Isotopes which are particularly useful for the purpose of the present invention are 125 1, 131 L 35 S,
- fluorophore it is also possible to label the antigen or antibody reagents with a fluorophore.
- fluorescently labeled antibody When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence of the fluorophore.
- fluorophores are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, fluorescamine or fluorescence-emitting metals such as Eu or other lanthanides. These metals are attached to antibodies using metal chelators.
- the antigen or antibody reagents useful in the present invention also can be detectably labeled by coupling to a chemiluminescent compound.
- a chemiluminescent- tagged antibody or antigen is then determined by detecting the luminescence that arises during the course of a chemical reaction.
- useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
- a bioluminescent compound such as a bioluminescent protein may be used to label the antigen or antibody reagent useful in the present invention. Binding is measured by detecting the luminescence.
- Useful bioluminescent compounds include luciferin, luciferase and aequorin.
- Detection of the detectably labeled reagent according to the present invention maybe accomplished by a scintillation counter, for example, if the detectable label is a radioactive gamma emitter, or by a fluorometer, for example, if the label is a fluorophore.
- the detection is accomplished by colorimetry to measure the colored product produced by conversion of a chromogenic substrate by the enzyme. Detection may also be accomplished by visual comparison of the colored product of the enzymatic reaction in comparison with appropriate standards or controls.
- the immunoassay of this invention may be a "two-site” or “sandwich” assay.
- the fluid containing the antibody being assayed is allowed to contact a solid support.
- a quantity of detectably labeled soluble antibody is added to permit detection and/or quantitation of the ternary complex formed between solid-phase antibody, antigen, and labeled antibody.
- Sandwich assays are described by Wide, Radioimmune Assay Method, Kirkham et al, Eds., E. & S. Livingstone, Edinburgh, 1970, pp 199-206.
- agglutination assays both direct and indirect, which are well known in the art.
- the agglutination of particles containing the antigen indicates the presence or absence of the corresponding antibody.
- Any of a variety of particles, including latex, charcoal, kaolinite, or bentonite, as well as microbial cells or red blood cells, may be used as agglutinable carriers (Mochida, US 4,308,026; Gupta et al, J. Immunol. Meth. 80:177-187 (1985); Castelan et al, J. Clin. Pathol.
- the present invention provides methods to detect and enumerate cells secreting an antibody specific for a mycobacterial antigen.
- a sample containing lymphocytes such as peripheral blood lymphocytes
- a reagent containing the antigen of interest As the antibody secreting cells of the sample secrete their antibodies, the antibodies react with the antigen, and the reaction is visualized in such a way that the number of antibody secreting cells (or plaque forming cells) may be determined.
- the antigen may be coupled to indicator particles, such as erythrocytes, preferably sheep erythrocytes, arranged in a layer.
- antibodies As antibodies are secreted from a single cell, they attach to the surrounding antigen- bearing erythrocytes. By adding complement components, lysis of the erythrocytes to which the antibodies have attached is achieved, resulting in a "hole” or “plaque” in the erythrocyte layer. Each plaque corresponds to a single antibody-secreting cell.
- the sample containing antibody-secreting cells is added to a surface coated with an antigen-bearing reagent, for example, a mycobacterial antigen alone or conjugated to bovine serum albumin, attached to polystyrene. After the cells are allowed to secrete the antibody which binds to the immobilized antigen, the cells are gently washed away.
- an antigen-bearing reagent for example, a mycobacterial antigen alone or conjugated to bovine serum albumin
- the present invention is also directed to a kit or reagent system useful for practicing the methods described herein.
- a kit will contain a reagent combination comprising the essential elements required to conduct an assay according to the disclosed methods.
- the reagent system is presented in a commercially packaged form, as a composition or admixture (where the compatibility of the reagents allow), in a test device configuration, or more typically as a test kit.
- a test kit is a packaged combination of one or more containers, devices, or the like holding the necessary reagents, and usually including written instructions for the performance of assays.
- the kit may include containers to hold the materials during storage, use or both.
- the kit of the present invention may include any configurations and compositions for performing the various assay formats described herein.
- kits for determining the presence of anti-Mtb early antibodies may contain one or more early Mtb antigens, either in immobilizable form or already immobilized to a solid support, and a detectably labeled binding partner capable of recognizing the sample anti-Mtb early antibody to be detected, for example, a labeled anti-human Ig or anti-human Fab antibody.
- a kit for determining the presence of an early Mtb antigen may contain an immobilizable or immobilized "capture” antibody which reacts with one epitope of an early Mtb antigen, and a detectably labeled second (“detection") antibody which reacts with a different epitope of the Mtb antigen than that recognized by the (capture) antibody.
- Any conventional tag or detectable label maybe part of the kit, such as a radioisotope, an enzyme, a chromophore or a fluorophore.
- the kit may also contain a reagent capable of precipitating immune complexes
- a kit according to the present invention can additionally include ancillary chemicals such as the buffers and components of the solution in which binding of antigen and antibody takes place.
- the present invention also provides an approach to the identification, isolation and characterization of early Mtb antigens.
- an adsorbed patient serum or pool of sera containing antibody for one or more antigens can be used in initial stages of antigen preparation and purification, as well as in the process of cloning of a protein antigen.
- This antiserum can be further adsorbed with an Mtb or other mycobacterial preparation to render it functionally monospecific or oligospecific.
- This "enriched" antiserum can be used along with standard biochemical purification techniques to assay for the presence of the antigen it recognizes in fractions obtained during the purification process.
- the antiserum can also be used in immobilized form as an immunoadsorbent in affinity purification of the antigen in accordance with standard methods in the art. hi addition, the antiserum can be used in an expression cloning method to detect the presence of the antigen in bacterial colonies or phage plaques where the antigen is expressed.
- the antigen can be used to immunize animals to prepare high titer antisera or, preferably, to obtain a mAb specific for that antigen.
- an animal antiserum or mAb can be employed advantageously in place of the patient antiserum or in combination with a test body fluid sample in a competition immunoassay.
- the antiserum or mAb can be used for antigen production or purification, or in an immunoassay for detecting the antigen, for example as a binding partner (either the capture antibody or the detection antibody) in a sandwich immunoassay.
- the present invention provides an immunoassay for detecting the presence of an Mtb early antigen in a body fluid or in a bacterial culture grown from a body fluid of a subject suspected of being infected with Mtb.
- a sensitive immunoassay such as a direct sandwich EIA or a competitive EIA can detect an Mtb protein (early antigen) in picogram amounts.
- a competitive assay allows detection of specific epitopes of the Mtb antigen without the necessity of starting with a purified antigen preparation. Such assays permits detection of Mtb in the patient sample at an earlier time than standard bacteriological analysis (i.e., appearance of colonies on agar).
- This method therefore provides a basis for clinical decisions to initiate therapy after several hours or days if the antigen can be detected in a body fluid. In any case, this is a major advantage over the conventional two to four (or more) weeks commonly needed to grow out Mtb organisms from a patient sample. The earlier the stage of the infection, the lower would be the titer of Mtb in a given body fluid, and the greater would be the advantage of the present assay over conventional diagnosis.
- a number of immunoassays for various Mtb antigens are known in the art and can serve as the basis for development of assays for the early antigens of the present invention (Wilkins et al, supra; Verbon, 1994, supra; Benjamin, RG et al, 1984, J. Med. Micro.
- test antigen preparation for example an Mtb culture supernatant or extract is added to the immobilized antibody.
- a second "detection" antibody such as a murine mAb specific for the same antigen or preferably for a different epitope of the same protein, allowed to bind in the presence of a fixed amount of a mAb, preferably of murine origin, specific for the epitope of interest.
- the detection mAb maybe enzyme-conjugated.
- a second step reagent such as an enzyme-labeled antibody specific for murine immunoglobulin may be used for detection of antigen which has become immobilized.
- the present invention permits isolation of an Mtb early antigen which is then used to produce one or more epitope-specific mAbs, preferably in mice. Screening of these putative early Mtb-specific mAbs is done using known patient sera which have been characterized for their reactivity with the early antigen of interest. The murine mAbs produced in this way are then employed in a highly sensitive epitope-specific competition immunoassay for early detection of TB. Thus, a patient sample is tested for the presence of antibody specific for an early epitope of Mtb by its ability to compete with a known mAb for binding to a purified early antigen. For such an assay, the mycobacterial preparation may be less than pure because, under the competitive assay conditions, the mAb provides the requisite specificity for detection of patient antibodies to the epitope of choice (for which the mAb is specific).
- the present invention provides a method to detect immune complexes containing early Mtb antigens in a subject using an EIA as described above. Circulating immune complexes have been suggested to be of diagnostic value in TB. (See, for example, Mehta, PK et al, 1989, Med. Microbiol. Immunol. 275:229-233; Radhakrishnan, VV et al, 1992, J. Med. Microbiol. 35:128-131). Methods for detection of immune complexes are well-known in the art. Complexes maybe dissociated under acid conditions and the resultant antigens and antibodies detected by immunoassay. See, for example, Bollinger, RC et al, 1992, J. Infec. Dis. 165:913-916. Immune complexes may be precipitated for direct analysis or for dissociation using known methods such as polyethylene glycol precipitation.
- Mtb early antigens as described herein are preferably produced using recombinant methods. See Example TV.
- Conventional bacterial expression systems utilize Gram negative bacteria such as E. coli or Salmonella species. However, it is believed that such systems are not ideally suited for production of Mtb antigens (Burlein, JE, In: Tuberculosis: Pathogenesis, Protection and Control, B. Bloom, ed., Amer Soc Microbiol, Washington, DC, 1994, pp. 239-252). Rather, it is preferred to utilize homologous mycobacterial hosts for recombinant production of early Mtb antigenic proteins or glycoproteins. Methods for such manipulation and gene expression are provided in Burlein, supra. Expression in mycobacterial hosts, in particular M.
- the present invention also provides a urine based diagnostic method for TB that can be used either as a stand-alone test, or as an adjunct to the serodiagnostic methods described herein.
- a urine based diagnostic method for TB that can be used either as a stand-alone test, or as an adjunct to the serodiagnostic methods described herein.
- Such a method enables the practitioner to (1) determine the presence of anti-mycobacterial antibodies in urine from TB patients with early disease (non-cavitary, smear negative TB patients) and from HTV-infected TB patients; (2) determine the profile of specific mycobacterial antigens, such as those in the culture filtrate, that are consistently and strongly reactive with the urine antibodies; and (3) obtain the antigens that are recognized by the urine antibodies.
- Serum and urine samples from non-cavitary and/or smear negative, culture positive TB patients and from HlV-infected TB patients are obtained Cohorts comprising PPD-positive and PPD-negative healthy individuals, non-tuberculous HIN-infected individuals, or close contacts of TB patients can serve as negative controls.
- the reactivity of the serum samples with culture filtrate proteins of M. tuberculosis, and the purified antigens (MPT 32, Ag 85C and the 88 kDa, as described herein) is preferably determined by ELISA as described herein. All sera are preferably depleted of cross-reactive antibodies prior to use in ELISA.
- the following description is of a preferred assay method and approach, and is not intended to be limiting to the particular steps (or their sequence), conditions, reagents and amounts of materials.
- E. coli lysates (suspended at 500 ⁇ g/ml) are coated onto wells of ⁇ LISA plates (Immulon 2, Dynex, Chantilly, NA.) and the wells are blocked with 5% bovine serum albumin (BSA).
- the serum samples (diluted 1:10 in PBS-Tween-20) are exposed to 8 cycles of absorption against the E. coli lysates. The adsorbed sera are then used in the ⁇ LISA assays.
- the antigen-antibody binding is allowed to proceed for 90 min at 37°C.
- the plates are washed 6 times with PBS-Tween 20 (0.05%) and 50 ⁇ l/well of alkaline phosphatase-conjugated goat anti-human IgG (Zymed, CA), diluted 1 :2000 in PBS/Tween 20 is added.
- the plates are washed 6 times with Tris buffered saline (50 mM Tris, 150 mM ⁇ aCl) and the Gibco BRL Amplification System (Life Technologies, Gaithersburg, MD) used for development of color.
- the absorbance is read at 490 nm after stopping the reaction with 50 ⁇ l of 0.3M H 2 SO 4 .
- the reactivity of the urine samples with the various antigens is determined initially with undiluted urine samples as described above.
- results obtained by the present inventors showed that the optimal concentration of the culture filtrate protein preparation is 125 ⁇ l/well of 4 ⁇ g/ml suspension, and for MPT 32 is 125 ⁇ l/well of 2 ⁇ g/ml.
- the urine is left overnight in the antigen coated wells: However, if urine antibody titers of smear-negative and HiN-infected patients are lower than those observed in smear positive patients, it may be necessary to first concentrate the urine samples. For concentration, Amicon concentrators with a molecular weight cut off of 30 kDa is preferred.
- Concentrated urine samples are evaluated for the presence of antibodies to the above mentioned antigens. Optimal conditions for these assays are determined readily. The sensitivity and specificity of antibody detection by use of one or more of the antigens, with both urine and serum samples is also readily determined.
- the present inventors Based on this map, the present inventors generated a 2-D map of the antigens that are recognized by the early serum antibodies (from smear-negative patients), antibodies from advanced, smear-positive HIV-uninfected TB patients, and from HIV-infected TB patients
- Screening permits the determination of whether additional antigens besides the MPT 32, Ag 85C and the 88 kDa protein are to be included in the assay for its optimization. It is preferred to determine if the anti-MPT 51 antibodies are well represented in the urine since this protein is highly recognized by serum antibodies during both early and late stages of TB, and its identity and sequence are known.
- Culture filtrate antigens of Mtb are fractionated on 2-D gels and transferred to obtain 2-D blots as described below. Briefly, 70 ⁇ g of culture filtrate proteins are resuspended in 30 ⁇ l of isoelectric focusing sample buffer (e.g., 9M urea, 2% NP-40, 5% ⁇ -mercaptoethanol, and 5% ampholytes at pH 3-10 or pH 4 - 6.5).
- the ampholytes used in the Examples below from Pharmacia are designated "PharmalytesTM" and are co-polymers of glycine, glycylglycine, amines and epichlorhydrin.
- the tube gels are soaked in sample transfer buffer for 30 min and then electrophoresed in the second dimension by using a 15% SDS-polyacrylamide gel. This is carried out at 20 mA per gel for 0.3 hrs followed by 30 mA per gel for 1.8 hrs.
- the separated proteins are then transferred for subsequent immunoblotting.
- the 2-D western blots are washed with PBS, and blocked for 2-2.5 hr. with 5% BSA. After washing the blots again, they are exposed to the individual urine samples (undiluted, or concentrated) overnight with shaking. After subsequent washing with PBS-Tween, the blots are exposed to alkaline-phosphatase conjugated anti-human IgG, and then to the appropriate substrate.
- the antigens that are reactive with the urine samples are identified on the basis of the 2-D maps already generated.
- Antigens that are strongly recognized by the urine antibodies, as well as by serum antibodies, are candidates for inclusion in the preferred diagnostic assay.
- Preferred antigens are the 88 kDa protein GlcB described above or is MPT 51 and epitopes thereof, such those present in the various peptides described above. DNA encoding these proteins or fragments or variants thereof are cloned and expressed.
- the Mtb culture filtrate preparation contains >100 different proteins (205 protein spots), and most of the proteins in the 49-76 kDa range are expressed in low abundance in the culture medium (Sonnenberg et al. , supra). This may be a result of growing Mtb is in minimal medium to obtain these proteins, to avoid difficulties associated with the proteins of enriched media (BSA, casein digests, etc.). If the immunoreactive protein is well- expressed in the culture filtrate, and reasonably isolated on the gel, it can be excised from the PVDF blot and sequenced. Since the entire genomic sequence of Mtb is known , the peptide sequence is used to identify the protein with complete precision.
- the nucleotide sequence of the gene (i.e., open reading frame) encoding that protein then becomes the basis for PCR amplification of the relevant DNA from genomic DNA, followed by cloning into an expression vector. Since many of the culture filtrate proteins are present in small quantities, an alternative, possibly more reliable, approach would utilize the urine antibodies to immunoscreen an expression library of Mtbs to obtain the gene(s) encoding the relevant protein(s). These approaches may be used, for example, to clone the MPT 51 gene or to identify the immunoreactive proteins in the 49-76 kDa region. For expression of MPT 51, the shuttle vector pW16 is preferred; this vector has an E.
- This vector can be used for expression in E. coli or in M. smegmatis. Since mycobacterial proteins expressed in E. coli host often show poorer immunological reactivity than the same proteins expressed in the mycobacterial host, it would be preferred to express the antigen inM. smegmatis. The methods for expression of genes in mycobacterial hosts are well described (Gaora, PO et al, 1997, Med. Principles Pract. 6:91).
- PCR amplification of the target gene using primers that contain restriction sites to generate in-frame fusions is performed.
- the PCR product is purified, and digested with the appropriate restriction enzymes and purified again.
- the vector D ⁇ A is cut with the appropriate restriction enzymes and purified.
- the PCR product and the vector are ligated, electroporated into DH5 ⁇ , and grown in the presence of hygromycin overnight.
- Several antibiotic-resistant colonies are grown in a small volume of medium, and the plasmid D ⁇ A isolated by miniprep. The size of the insert is checked in these colonies. Inserts from one or more colonies are sequenced.
- the bacteria are grown shaking in 7H9 medium till they reach an absorbance of 0.8-1.0.
- the bacteria are harvested, washed twice with ice cold water, once with ice-cold 10% glycerol and suspended in the same.
- An aliquot of the cells are electroporated with the plasmid D ⁇ A from the colony whose insert was sequenced.
- the electroporated cells are grown for 3-4 hrs in 7H9, and plated on antibiotic containing plates. Several resistant colonies are grown in minimal media for 48-72 hrs. The M.
- smegmatis cell pellets are sonicated, the lysates fractionated by SDS-PAG ⁇ and the presence of the immunoreactive protein confirmed by reactivity with the antibody-containing urine samples.
- Colonies which express the desired protein are expanded, and the His-tagged recombinant protein is purified using of commercially available ⁇ ickel-agarose columns (Qiagen).
- the reactivity of the recombinant protein with the entire cohort of urine samples is evaluated by ⁇ LISA as described herein. Combinations of antigens, preferably of individual epitopes, that provide the best sensitivity and specificity are delineated.
- an expression library of Mtb genomic DNA is screened with the antibody-positive urine samples. A pool of TB patient urine samples (which show strong reactivity on western blots with culture filtrate proteins of Mtb) from 10-15 TB patients is adsorbed against E. coli lysate, and used at an appropriate dilution to screen the library.
- E. coli Y1090 infected with appropriate plaque forming units of the phage from the library are plated in top agar on LB plates. After 2.5 hrs at 42°C, isopropyl ⁇ -D thiogalactoside (IPTG) saturated nitrocellulose filters are overlaid on the top of the plates for 2.5 hrs at 37°C. The filters are removed, washed extensively, and exposed to the pooled urine overnight. After washing again, the filters are exposed to 1 : 1000 dilution of Alkaline
- Phosphatase conjugated anti-human IgG followed by BCIP-NBT substrate.
- the positive plaques are located on the original plates, excised and re-screened till purified.
- the screening of the library by the urine antibodies can be expected to identify several proteins.
- the cloned phages are used to establish lysogens in E. coli Y1089. Single colonies from lysogens are grown in LB medium at 32°C till an absorbance (at 600 nm) of 0.5 is obtained.
- the lysogens are induced to express the recombinant proteins by raising the temperature to 45°C and addition of IPTG (10 mM). The cultures are grown for additional 1.5 hrs at 37°C to allow accumulation of the recombinant proteins, and the bacterial pellets are obtained.
- the pellets are sonicated in small volume of PBS and the lysates fractionated on 10% SDS-PA gels and electroblotted onto nitrocellulose membranes.
- the blots are probed with individual urine samples from 20-25 TB patients, and clones coding for strongly immuno-reactive proteins recognized by all or a vast majority of the urine samples are identified. Lysates from E. coli Y1089 alone or Y1089 lysogenized with lambda gtl 1 vector are used as controls.
- DNA from the recombinant clones encoding strongly immunoreactive proteins is isolated by the commercial Wizard Lambda Preps DNA Purification system (Promega), digested with ⁇ coRl and the insert obtained.
- the insert DNA from the clone(s) is subcloned into pG ⁇ M ⁇ X-1 vector (Promega) whose reading frame at the EcoRI cloning site is identical to lambda gtl 1.
- Competent E. coli JM 109 cells are transformed with the recombinant plasmid (pGEMEX plus insert from the clone(s)).
- Plasmid DNA is isolated using Wizard Plus Minipreps (Promega), and used for automated sequencing with primers from SP6 and T3 promoter specific primers flanking the multiple cloning site in the PGEMEX- 1 followed by 'primer- walking'.
- the nucleotide sequence is used in similarity searches against the Mtb genomic sequence to identify the protein and to obtain the sequence of the whole gene. Once the protein has been identified and the sequence of the gene is known, cloning it for expression is done as was described above for the exemplary cloning of the MPT 51 gene.
- the vaccine compositions and methods are designed to augment this immunity, and preferably, to induce it a stage wherein the bacterial infection can be prevented or curtailed.
- the vaccine compositions are particularly useful in preventing Mtb infection in subjects at high risk for such an infection, as discussed above.
- the vaccine compositions and methods are also applicable to veterinary uses.
- this invention includes a vaccine composition for immunizing a subject against Mtb infection.
- An Mtb early antigen preferably one of the four described herein in more detail or a peptide thereof, is prepared as the active ingredient in a vaccine composition.
- These four proteins are (a) the 88 kDa protein having a pi of about 5.2 and SEQ ID NO: 106; (b) the protein characterized as Mtb antigen 85C; (c) the protein characterized as Mtb antigen MPT51 (SEQ ID NO: 107); and (d) the glycoprotein characterized as Mtb antigen MPT32.
- the vaccine may also comprises one or more of the proteins described herein, peptides thereof or functional derivatives as described, or DNA encoding the protein, and a pharmaceutically acceptable vehicle or carrier.
- Preferred peptides for use in a vaccine composition, alone, in combination, or in linear multimers, include the 23 peptide described above in the context of diagnostic compositions.
- the vaccine comprises a fusion protein or peptide multimer which includes an Mtb early antigen, e.g., a full length protein and/or one or more of the above peptides, as described above.
- the vaccine composition may further comprise an adjuvant or other immune stimulating agent.
- an adjuvant or other immune stimulating agent for use in vaccines, the Mtb early antigen protein or epitope-bearing peptide thereof is preferably produced recombinantly, preferably in prokaryotic cells.
- Full length proteins or longer epitope-bearing fragments of the Mtb early antigen proteins are preferred immunogens, in particular, those reactive with early antibodies. If a shorter epitope-bearing fragment, for example containing 20 amino acids or less, is the active ingredient of the vaccine, it is advantageous to couple the peptide to an immunogenic carrier to enhance its immunogenicity.
- an immunogenic carrier to enhance its immunogenicity.
- Such coupling techniques are well known in the art, and include standard chemical coupling techniques using linker moieties such as those available from Pierce Chemical Company, Rockford, Illinois.
- Suitable carriers are proteins such as keyhole limpet hemocyanin (KLH), E. coli pilin protein k99, BSA, or rotavirus NP6 protein.
- Another vaccine embodiment is a peptide multimer or fusion protein which comprise the Mtb early antigen protein or an epitope-bearing peptide region fused linearly to an additional amino acid sequence. Because of the ease with which recombinant materials can be manipulated, multiple copies a selected epitope-bearing region may be included in a single fusion protein molecule. Alternatively, several different epitope-bearing regions can be "mixed and matched" in a single multimer or fusion protein.
- the active ingredient such, preferably a recombinant product, is preferably administered as a protein or peptide vaccine, i another embodiment, the vaccine is in the form of a strain of bacteria (preferably a known "vaccine strain") which has been genetically transformed to express the protein or epitope-bearing peptide.
- a strain of bacteria preferably a known "vaccine strain”
- Salmonella dublin live vaccine strain SL5928 aroA148fliC(i)::InlO and S. typhimurium LB5000 hsdSB121 leu-3121 Newton S. M. et al, Science 1989, 244: 70
- a Salmonella strain expressing the Mtb protein or fragment of this invention may be constructed using known methods.
- a plasmid encoding the protein or peptide may first be selected in an appropriate host, e.g., E. coli strain MCI 061.
- the purified plasmid is then introduced into S. typhimurium strain LB5000 so that the plasmid DNA is be properly modified for introduction into Salmonella vaccine strains.
- Plasmid DNA isolated from LB5000 is introduced into, e.g., S. dublin strain SL5928 by electroporation. Expression of the Mtb protein or fragment encoded by the plasmid in SL5928 can be verified by Western blots of bacterial lysates and antibodies specific for the relevant antigen or epitope.
- the active ingredient, or mixture of active ingredients, in protein or peptide vaccine composition is formulated conventionally using methods well-known for formulation of such vaccines.
- the active ingredient is generally dissolved or suspended in an acceptable carrier such as phosphate buffered saline.
- Vaccine compositions may include an immunostimulant or adjuvant such as complete or incomplete Freund's adjuvant, aluminum hydroxide, liposomes, beads such as latex or gold beads, ISCOMs, and the like.
- an immunostimulant or adjuvant such as complete or incomplete Freund's adjuvant, aluminum hydroxide, liposomes, beads such as latex or gold beads, ISCOMs, and the like.
- 0.5 ml of Freund's complete adjuvant or a synthetic adjuvant with less undesirable side effects is used for intramuscular or subcutaneous injections, preferably for all initial immunizations; this can be followed with Freund's incomplete adjuvant for booster injections.
- General methods to prepare vaccines are described in Remington 's Pharmaceutical
- Liposomes are pharmaceutical compositions in which the active protein is contained either dispersed or variously present in corpuscles consisting of aqueous concentric layers adherent to lipidic layers.
- the active protein is preferably present in the aqueous layer and in the lipidic layer, inside or outside, or, in any event, in the non-homogeneous system generally known as a liposomic suspension.
- the hydrophobic layer, or lipidic layer generally, but not exclusively, comprises phospholipids such as lecithin and sphingomyelin, steroids such as cholesterol, more or less ionic surface active substances such as dicetylphosphate, stearylamine or phosphatidic acid, and/or other materials of a hydrophobic nature.
- Adjuvants, including liposomes are discussed in the following references, incorporated herein by reference:
- the vaccine compositions preferably contain (1) an effective amount of the active ingredient, that is, the protein or peptide together with (2) a suitable amount of a carrier molecule or, optionally a carrier vehicle, and, if desired, (3) preservatives, buffers, and the like.
- an effective amount of the active ingredient that is, the protein or peptide together with (2) a suitable amount of a carrier molecule or, optionally a carrier vehicle, and, if desired, (3) preservatives, buffers, and the like.
- the immunogenically effective amounts of the proteins or peptides of the invention must be determined empirically. Factors to be considered include the immunogenicity of the native peptide, whether or not the peptide will be complexed with or covalently attached to an adjuvant or carrier protein or other carrier and the route of administration for the composition, i.e., intravenous, intramuscular, subcutaneous, etc., and the number of immunizing doses to be administered. Such factors are known in the vaccine art, and it is well within the skill of the immunologists to make such determinations without undue experimentation.
- the vaccines are administered as is generally understood in the art. Ordinarily, systemic administration is by injection; however, other effective means of administration are known. With suitable formulation, peptide vaccines may be administered across the mucus membrane using penetrants such as bile salts or fusidic acids in combination, usually, with a surfactant. Transcutaneous administration of peptides is also known. Oral formulations can also be used. Dosage levels depend on the mode of administration, the nature of the subject, and the nature of carrier/adjuvant formulation. Preferably, an effective amount of the protein or peptide is between about 0.01 ⁇ g/kg -1 mg/kg body weight.
- Subjects may be immunized systemically by injection or orally by feeding, e.g., in the case of vaccine strains of bacteria, 10 -10 bacteria on one or multiple occasions.
- multiple administrations of the vaccine in a standard immunization protocol are used, as is standard in the art.
- the vaccines can be administered at approximately two to six week intervals, preferably monthly, for a period of from one to four inoculations in order to provide protection.
- Vaccination with the vaccine composition will result in an immune response, either or both of an antibody response and a cell-mediated response, , which will block one or more steps in the Mtb bacterium's infective cycle, preferably the steps of binding to and entry into host cells in which it grows.
- the study population included 58 HIV neg individuals with confirmed pulmonary TB. Of these, 16 were individuals attending the Infectious Disease Clinic at the Veterans Affairs Medical Center, New York. All patients were Mtb culture-positive, 9/16 patients were smear- negative, 14/16 showed minimal to no radiological lesions, and all were bled either prior to, or within 1-2 weeks of initiation of chemotherapy for TB. Eight sera were obtained from Leonid Heifitz and Lory Powell (National Jewish Center, Denver, CO). An additional 20 sera were provided by J.M. Phadtare ( Grant Medical College, Bombay, India). Fourteen serum samples obtained from Lala Ram Sarup Tuberculosis Hospital, Mehrauli, New Delhi, India were provided by S. Singh. A majority of these 42 patients were smear-positive, had radiological appearance of moderate to advanced pulmonary lesions and were bled 4-24 weeks after initiation of chemotherapy. The control populations consisted of the following groups:
- Group (b) subjects were included because TB has emerged as a major opportunistic disease in the HTV-infected population.
- the antigen preparations were total cellular sonicate (CS), total culture filtrate (CF), lipoarabinomannan (LAM), LAM-free culture filtrate proteins (LFCFP), whole cell walls (CW),
- SDS-soluble cell wall proteins SDS-soluble cell wall proteins (SCWP), and cell wall core (CWC), all isolated from Mtb H 37 Rv.
- CS was obtained from Mtb grown in Middlebrook 7H9 broth (Difco Laboratories, Detroit, MI) for 2-3 weeks.
- the bacilli were harvested by centrifugation at 1000 rpm for 30 min and the pellet resuspended in phosphate buffered saline (PBS) containing PMSF, EDTA and DTT at a final concentration of ImM each.
- PBS phosphate buffered saline
- the suspension was frozen in liquid nitrogen and thawed (several times) to weaken the cell walls, followed by sonication for 20 min at 4°C.
- the sonicate was centrifuged for 10 min at 10,000 rpm and the supernatant collected.
- Mtb was grown to mid-logarithmic phase (14 days) in glycerol-alanine-salts medium.
- the cells were removed by filtration through a 0.22 ⁇ m membrane, and the culture supernatant was concentrated by ultrafiltration using an Amicon apparatus (Beverly, MA) with a 10,000 MW cut-off membrane.
- the concentrated material (CF) was dialyzed against 100 mM ammonium bicarbonate and dried by lyophilization.
- CF was suspended (7mg/ml) in a buffer containing 50mM Tris HCI (pH 7.4), and 150mM NaCl, following which 20% Triton X-114 was added to obtain a final concentration of 4%.
- the suspension was allowed to rock overnight at 4°.
- a biphasic partition was set up by warming the 4% Triton X-114 suspension to 37° for 40 minutes, followed by centrifugation at 12,000 x g.
- the aqueous phase was re-extracted twice with 4% Triton X-114 to ensure complete removal of the lipoarabinomannan, lipomannan (LM) and phosphatidyl-inositol- mannoside (PPM).
- LM lipomannan
- PPM phosphatidyl-inositol- mannoside
- the final aqueous phase was precipitated with 10 volumes of cold acetone, and the pellet washed several times with cold acetone to remove residual Triton X-114.
- the LAM-free aqueous phase CFPs were suspended in 100 mM ammonium bicarbonate, aliquoted and dried by lyophilization.
- LAM, LM and PIM were extracted from whole cells by mechanical lysis of the bacilli in PBS (pH 7.4) containing 4% Triton-X 114 in a Bead Beater (Biospec Products, Bartelsville, OK). Unbroken cells and cell wall material were removed by centrifugation at 12000g, 4° for 15 min. The supernatant was collected and a biphasic partition set up. The detergent phase was obtained, back-extracted several times with cold PBS and the macromolecules in the final detergent phase were precipitated with 10 volumes of cold acetone. The precipitate was collected by centrifugation and allowed to air dry. This material (which contained the lipoglycans) was suspended in PBS and residual proteins were removed by extraction with PBS- saturated phenol.
- aqueous phase was collected and, after dialyses against distilled water, the lipoglycans were lyophilized.
- LAM was further purified away from LM and PIM by size exclusion chromatography as previously described (Chatteriee, D. et al, 1992, J. Biol. Chem. 269:66222,-66233).
- Mtb cells were inactivated by isothermal killing at 80° for 1 h and suspended at a concentration of 0.5g cells/ml, in a buffer containing PBS, pH 7.4, 4% Triton X- 114, PMSF, pepstatin, EDTA, and DNase.
- the cells were disrupted in a Bead Beater using 0.1 mm Zirconia beads.
- the lysed cells were first centrifuged at 3000 x g for 5 min to remove unbroken cells followed by centrifugation at 27,000 x g, 4° for 20 min.
- the resulting pellet was washed three times with cold PBS at room temperature. This final pellet was termed the CW.
- the SCWP were obtained by washing the CW twice with 2% SDS in PBS, pH 7.4 at room temperature.
- the tightly associated proteins were isolated by extracting the CW pellet three times with 2% SDS in PBS, pH 7.4, at 55°.
- the 55°, 2% SDS extract was recovered, and the SDS was removed by using an Extracti Gel column (Pierce, Rockford, EL). The eluate from the column was dialyzed against twice-distilled H 2 O, aliquoted and dried by lyophilization.
- the CWC mycolyl-arabinogalactan-peptidoglycan complex
- the SDS- insoluble material obtained after extraction of the SCWP was suspended in PBS, 1% SDS, 0. lmg/ml proteinase K and incubated for 20h at 50°.
- the insoluble material was pelleted by centrifugation, washed twice with 2% SDS at 95° for lh and collected by centrifugation. This was washed several times with water and 80% acetone to remove SDS.
- Fractionation of LFCFP by size was performed by using a preparative SDS-PAGE system (model 491 Prep cell, Bio-Rad, Hercules, CA).
- CFP (20-25 mg) was loaded directly onto a 30ml 10% preparative polyacrylamide tube gel containing a 6% stacking gel, that was poured in a casting tube with a 37mm internal diameter.
- the running buffer used consisted of 25mM Tris, pH 8.3, 192mM glycine, 0.1% SDS.
- the proteins were separated by electrophoresis using an increasing wattage gradient of 8W for 3.13h, 12W for 2.5h, and finally 20W for 11. lh.
- Proteins were eluted from the bottom of the tube gel with a constant flow of 5mM sodium phosphate, pH 6.8. The initial 65ml of eluant were collected as the void volume, after which 80 fractions of 4.2 ml were collected at a rate of 0.4ml/min. Individual fractions were assayed by one dimensional SDS-PAGE and were pooled accordingly. SDS was removed from the pooled concentrated fractions by elution through an Extracti-Gel (Pierce) column. The pooled fractions were dried and stored frozen until testing. Adsorption of sera with E. coli sonicate
- E. coli Y1090
- Luria-Bertani medium Overnight cultures of E. coli (Y1090) grown in Luria-Bertani medium were centrifuged to obtain bacterial pellets that were treated as described for the Mtb sonicate, except that sonication was performed for 30 sec.
- BSA bovine serum albumin
- HTV was inactivated by addition of Triton X-100 (1% final concentration) to each serum sample, followed by heating at 55° for 60 min.
- Samples from non-HIN infected individuals were treated in the same manner to maintain consistency in sample preparation.
- Serum from each individual (20 ⁇ l) was diluted to 200 ⁇ l in PBS/Tween 20 (0.05%) in a 96-well tissue culture plate.
- the diluted serum samples were transfereed to the E. coli-coated, blocked ELISA plate by using a multichannel pipetter.
- the sera samples were exposed to the bound E. coli antigens for 90 min after which they were transferred to another ELISA plate that had been coated with E. coli and blocked as above.
- the serum samples were exposed to 8 cycles of adsorption with E.
- coli antigens following which they were transferred to a 96-well tissue culture plate where sodium azide (ImM final concentration) was added to each well. This protocol allows rapid and efficient processing of small volumes of multiple samples. Adsorbed serum samples were used within one week.
- the antigen-antibody binding was allowed to proceed for 90 min at 37°, following which the plates were washed 6 times with PBST. Fifty ⁇ l of alkaline phosphatase-conjugated goat anti-human IgG (Zymed, CA), diluted 1 :2000 (in the same diluent as the serum samples) were added to each well. After 60 min the plates were washed 6 times with Tris-buffered saline (50mM Tris, 150mM ⁇ aCl) and the Gibco BRL Amplification System (Life Technologies, Gaithersburg, MD) used for development of color. The plates were read at 490 nm after stopping the reaction with 50 ⁇ l of 0.3M H 2 SO 4 . The optimal antigen and antibody concentrations for each antigen were determined by checkerboard titration with limited numbers of control and non-TB sera prior to performing the ELISA with the total serum panel.
- the ELISA with each of the sized fractions generated by preparative polyacrylamide gel electrophoresis was performed as described as above, except that antigen was coated at 2 ⁇ g/ml and the sera were tested at a final dilution of 1 :200. Forty-two TB sera and 44 non-TB controls (16 PPD + ; 7 HTV neg , PPD neg ; and 21 HrV ⁇ , asymptomatic individuals) were included in these assays.
- the "IT" designations are World Health Organization standards for its collection of anti- Mtb antibodies.
- the alternative names of the mAbs, the antigens they recognize and the laboratory of origin are provided in Engers, H. et al. , 1986, Infect. Immun. 51:118-720;
- the second antibody was an alkaline phosphatase-conjugated rabbit anti-mouse IgG or goat anti-rabbit IgG (1:2000, Sigma Immunochemicals) added in a volume of 50 ⁇ l/well. SDS-PAGE and immunoblotting
- the cutoff for positivity in all ELISA assays was set to be the mean absorption or optical density (OD) ⁇ 3 standard deviations (SD) of the control group.
- the Wilcoxon signed rank test for paired samples was used to compare reactivity of sera pre- and post-adsorption.
- the SD of the above two groups were compared by using the F test.
- the reactivity of TB sera with LFCFP was compared to the reactivity with the other antigen preparations by using McNemar's paired test.
- the Graphpad Instat program was used for all statistical analyses.
- Antibodies reactive with LFCFP were detectable in 25/42 (60%) of the unadsorbed TB sera ( Figure 1).
- anti-mycobacterial antibodies were detectable in 4/17 (24%) additional, previously negative sera, raising the sensitivity to 69% ( Figure 1).
- a Wilcoxon signed rank test comparing the preadsorbed and post adsorbed sera.
- b F test comparing the standard deviations of the preadsorbed and post adsorbed sera.
- NS not significant.
- Antibodies to an 88kDa Secreted Antigen of M. tuberculosis Serve as a Surrogate Marker of Pre-clinical TB in HIV-infected Subjects
- HTV/TB HTV-infected individuals attending the Infectious Disease Clinic at the V. A. Medical Center, New York, who developed or presented with TB (HIV/TB) during the last several years. A total of 259 serum samples were available from these individuals. Of these samples: (a) 136 were obtained from 38 patients on several occasions prior to manifestation of clinical TB ("HTV/pre-TB");
- non-HIV TB patients Sera from 20 non-HIV TB patients (non-HTV/TB), 19 of whom were smear-positive, and all of whom showed radiological evidence of moderate to advanced cavitary disease, were included as positive controls. Sera from 19 non-HTV/ PPD skin test-positive individuals were included as negative controls.
- the study included (i) sera from 35 HTV-infected, asymptomatic individuals, with CD4 cell counts >800 and (ii) 48 serum samples from 16 HTV-infected subjects whose blood cultures were positive for Mycobacterium avium-intracellulare ("HIV/MAI"). Of these, 28 HIV/MAI serum samples were obtained during the months preceding advent of MAI bacteremia.
- LAM-free culture filtrate proteins were prepared as described in Example I. This antigen mixture was subsequently fractionated based on the molecular weight of the proteins using a BioRad 491 Prep Cell (Hercules, CA) with a 30 ml 10% preparative polyacrylamide tube gel containing a 6% stacking gel as above. Fractions were pooled according to molecular weights (as determined by SDS- PAGE) and dried. The LFCFP and the sized fractions thereof, were resolved on 10% SDS-PA mini gel and transferred onto a nitrocellulose membrane prior to probing with sera.
- LAM-free culture filtrate proteins LAM-free culture filtrate proteins
- the second antibody used was alkaline-phosphatase conjugated rabbit anti- human IgG and the substrate was BCIP/NBT (Kirkegaard and Perry Laboratories, Gaithersburg, MD). All sera were adsorbed with E. coli lysates prior to use in ⁇ LISA assays. Adsorptions and ⁇ LISAs were performed as described in Example I.
- the specificity of the anti-Mtb antibody responses in the HTV/TB patients was evaluated.
- Anti-Mtb antibodies were tested in multiple sera from 6 antibody- positive, 3 antibody-negative HIN/TB patients, and 3 HIN/MAI patients. All 6 antibody- positive individuals had circulating antibodies for different intervals during the years preceding the clinical manifestation of TB. One of the six patients developed anti-Mtb antibodies about 1.5 yr before clinical diagnosis of TB, and another about 4.5 yr prior to that time. The remaining 4 patients had circulating antibodies for the preceding 5-6 yr. In contrast, similar samples from 3 antibody-negative HTV/TB patients and 3 HTV/MAI bacteremia patients were consistently negative.
- LFCFP were probed with sera from nine ELISA "1" HTV/TB (two HTV/at-TB, seven HTV/pre-TB) and three non-HTV/TB patients. These results were compared to the antibody reactivity of six HIN- + asymptomatic controls and five non-HIN/PPD + healthy controls (ELISA neg ). As described in Example I, all sera (healthy and disease) reacted with antigens of 65kDa and 30-32kDa. The sera from non-HTV/TB patients reacted with multiple antigens (approximately 20) ranging in size from about 26kDa to about 115kDa.
- the LFCFP material was fractionated into 14 overlapping fractions based on molecular weight. Identification of fractions containing strongly seroreactive proteins was achieved by probing Western blots with pooled sera from six ELISA 4" non-HTV/TB or six HTV/TB patients. Besides the 65 kDa and 30-32 kDa antigens which were previously shown (Example I) to be reactive with all sera (healthy and disease), the non-HTV/TB serum pool reacted primarily with antigens with molecular weights above 30-32 kDa in fractions 6-14.
- HTV/TB patients recognize only a subset. For example, antibodies to the 38 kDa antigen are not found in HTV/TB, whereas antibodies to antigens in fraction 10-fraction 14, and in particular to the 88 kDa antigen are maintained despite HTV infection.
- HTV/PPD + control sera as cutoff 16/20 (80%) non-HTV/TB sera had antibodies to the total LFCFP.
- Example I the non-HTV/TB patients who were reactive with the unfractionated LFCFP were also reactive with the antigens in fraction 14 in this study
- the reactivity of HTV/TB sera with the unfractionated LFCFP and antigens in fraction 14 was also analyzed by comparing HTV/pre-TB and HTV/at-TB groups. Thirty-one percent of the HTV/at-TB were reactive with the total LFCFP, as were 55% of the HTV/pre-TB sera, hi contrast, 66% of the HTV/at-TB, and 74% of the HTV/pre-TB sera had antibodies which bound fraction 14 antigens.
- Example I shows that the 88 kDa antigen (GlcB) (present in Fraction 15 in that study, but present in Fraction 14 in the study of Example U) is one of the secreted antigens of Mtb that elicits antibodies during early stages of disease progression (in non-HTV TB patients).
- the detection of anti-88 kDa antibodies in the high risk HTV-infected population can serve as a diagnostic test, and the antibody as a surrogate marker, for identifying individuals with active pre-clinical TB.
- PPD 4" Fritzgerald J.M. et al.
- HIN patients who are anergic to PPD are large, ranging from 33% in Zaire to over 90% in Brazil, and ranges from 43% in early HTV infection to 100% in advanced HTV disease (Raviglione et al, 1992, supra). Delayed hypersensitivity skin test reactivity is known to be unstable in HTV individuals.
- the A-60 antigen used by some investigators provides poor sensitivity and poor specificity even in the non- HTV/TB patients, a group known to have higher antibody levels (Charpin D et al, Am Rev Respir Dis 1990, 242:380-384; Qadri, S. et al, Can J Microbiol 1991, 35:804-806).
- Anti-mycobacterial antibodies in seemingly antibody-negative patients may be circulating in the form of immune complexes with the antigens, thereby obscuring the presence of antibody in the assay used. That this may occur in at least a proportion of the patients is suggested by the increased frequency of antibodies detected in HTV/post-TB sera.
- the present results suggest that patients with persistently circulating antibodies to the
- Mtb 88 kDa antigen, GlcB may benefit from preventive anti-TB therapy, as has been found to be the case with PPD 4" HTV-infected individuals (Shafer, et al, supra; Pape, J.W. et al, Lancet 1993, 342:268-272).
- the patients in the present inventors' cohort were chosen on the basis of clinical confirmation of TB. Their PPD reactivity is not known.
- the length of time from a positive PPD skin test to the development of clinical disease ranges from 1-7 years in HIN- infected individuals (Selwyn et al, supra; Huebner et al, supra. There is no parameter which assists in determining the most appropriate time and duration of prophylactic anti-TB therapy.
- CFPs culture filtrate proteins
- Culture filtrates include not only actively secreted proteins but also somatic molecules that are released into the medium during replication or by autolysis .
- the protein profile of the culture filtrate is highly dependent on cultivation time. Further, the medium used and the means of incubation (static vs. shaking) may also impact on the profile of CFP .
- the protocol used for CFP preparation a clear understanding of the protein composition of this fraction is difficult to obtain from the current literature.
- the present inventors have combined 2-D PAGE, western blot analysis, N-terminal amino acid sequencing and liquid chromatography-mass spectrometry-mass spectrometry (LC-MS-MS) to develop a detailed map of culture filtrate proteins and have obtained the partial amino acid sequences for five previously undefined, relatively abundant proteins within this fraction which are found to be useful as early antigens for serodiagnosis of TB.
- LC-MS-MS liquid chromatography-mass spectrometry-mass spectrometry
- Mtb strains H37Rv (ATCC 27294) and H37Ra (ATCC 25177) were obtained from American Type Culture Collection (Rockville, MD).
- Mtb strain Erdman (TMC 107) was obtained from the Trudeau Mycobacterial Collection. Initially, each Mtb strain was inoculated from a 1 ml frozen stock into 10 ml of glycerol alanine salts (GAS) media; three such cultures were prepared for each strain. After incubation at 37°C for 14 days with gentle agitation each 10 ml culture was passed two more times increasing the volume of media by ten times for each pass. The resulting one liter cultures were termed pass number four.
- GAS glycerol alanine salts
- mAb A3h4 was obtained from Drs. P.K. Das and A. Rambukana, University of Amsterdam, Amsterdam, The Netherlands and mAbs F 126-2 and HYB 76-8 were obtained from Dr. A.Kolk, Royal Tropical Institute, Amsterdam, The Netherlands, and Dr. I. Rosenkrands, Statens Seruminstitut, Copenhagen, Denmark, respectively. All other mAbs were supplied through the WHO Monoclonal Antibody Bank then maintained by Dr. T. Shinnick, CDC, Atlanta, Georgia. Anti-MPT63 polyclonal serum was provided by Dr. H. Wiker, University of Oslo, Norway. Dr. S. Nagai provided polyclonal sera specific for MPT 32, MPT 35, MPT 46, MPT 53, and MPT 57.
- 2-D PAGE separation of proteins was achieved by the method of O'Farrell with minor modifications. Specifically, 70 ⁇ g of CFP was dried and suspended in 30 ⁇ l of isoelectric focusing (TEF) sample buffer (9M urea, 2% NP-40, 5% ⁇ -mercaptoethanol, and 5% ampholytes pH 3 - 10 (Pharmacia Biotech, Piscataway, NJ)), and incubated for 3 h at 20°C. An aliquot of 25 ⁇ g of protein was applied to a 6% polyacrylamide TEF tube gel (1.5 mm by 6.5 cm) containing 5% Pharmalytes pH 3 - 10 and 4 - 6.5 in a ratio of 1 :4.
- TEF isoelectric focusing
- the proteins were focused for 3 h at 1 kN using 10 mM H 3 PO 4 and 20 mM NaOH as the catholyte and anolyte, respectively.
- the tube gels were subsequently imbibed in sample transfer buffer for 30 min and placed on a preparative SDS-polyacrylamide gel (7.5 x 10 cm x 1.5 mm) containing a 6% stack over a 15% resolving gel.
- Electrophoresis in the second dimension was carried out at 20 mA per gel for 0.3 h followed by 30 mA per gel for 1.8 h. Proteins were visualized by staining with silver nitrate.
- Proteins subjected to 2-D or SDS-PAGE, were transferred to nitrocellulose membranes (Schleicher and Schuell, Keene, NH.) which were blocked with 0.1% bovine serum albumin in 0.05 M Tris-HCl, pH 7.5, 0.15 M NaCl, and 0.05% Tween 80 (TBST). These membranes were incubated for 2 h with specific antibodies diluted with TBST to the proper working concentrations (Table 2). After washing, the membranes were incubated for 1 h with goat anti- mouse or -rabbit alkaline phosphatase-conjugated antibody (Sigma) diluted in TBST. The substrates nitro-blue-tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate (BCTP) were used for color development.
- BCTP 5-bromo-4-chloro-3-indoyl phosphate
- the total protein population was conjugated to digoxigenin by incubating the membrane for one hour at room temperature in a solution of 0.05 M K 2 HPO 4 , pH 8.5 containing 0.3 ng/ml digoxigenin-3- O-methylcarbonyl- ⁇ -amino-caproic acid N-hydroxysuccinimide ester and 0.01 % Nonidet-P40.
- the membranes were subsequently blocked with a solution of 3% bovine serum albumin in 0.05 M Tris-HCl, pH 7.5, 0.15 M NaCl (TBS) for 1 h followed by washing with TBS. Incubation with specific antibodies was performed as described, followed by incubation of the membranes with mouse anti-DIG-Fab fragments conjugated to alkaline phosphatase diluted 1 :2000 in TBS, for 1 h. The membranes were washed three times with TBS and probed with goat anti-mouse or -rabbit horse radish peroxidase-conjugated antibody.
- TBS Tris-HCl, pH 7.5, 0.15 M NaCl
- CFPs 200 ⁇ g were resolved by 2-D PAGE and transferred to polyvinylidene difluoride membrane (Millipore, Milford, Mass.) by electroblotting at 50 V for 1 h, using CAPS buffer with 10% methanol. The membrane was stained with 0.1% Coomassie brilliant blue in 10% acetic acid and destained with a solution of 50% methanol and 10% acetic acid. Immobilized proteins were subjected to automated Edman degradation on a gas phase sequencer equipped with a continuous-flow reactor. The phenylthiohydantoin amino acid derivatives were identified by on-line reversed- phase chromatography as described previously. 7.
- LC-MS-MS analysis 200 ⁇ g was resolved by 2-D PAGE and transferred to polyvinylidene difluoride membrane (Millipore, Milford, Mass.) by electroblotting at 50 V for 1 h, using CAPS buffer with 10% methanol. The membrane was stained with 0.1% Coomassie brilliant blue in 10% acetic acid and destained with
- CFPs were subjected to LC-MS-MS to determine the sequence of internal peptide fragments.
- CFPs 200 mg were resolved by 2-D PAGE and the gel stained with 0.1% Coomassie brilliant blue and destained as described for proteins immobilized to PVDF membranes.
- the protein of interest was excised from the gel, washed several times with distilled water to remove residual acetic acid and subjected to in-gel proteolytic digestion with trypsin.
- Peptides were eluted from the acrylamide and separated by CI 8 capillary RP-HPLC.
- the microcapillary RP-HPLC effluent was introduced directly into a Finnigan-MAT (San Jose, CA) TSQ-700 triple sector quadrupole mass spectrometer. Mass spectrometry and analysis of the data was performed as described by Blyn et al.. C. RESULTS
- N-terminal amino acid sequencing of selected CFPs The N-terminal amino acid sequences or complete gene sequences and functions of several of the CFPs of Mtb, mapped with the available antibodies, are known. However, such information is lacking for the proteins that reacted with IT-42 IT-43, IT-44, IT-45, IT-51, IT-52, IT-53, IT-57, IT-59 and IT-69, as well as several dominant proteins not identified by these means. Of these, the most abundant proteins (IT-52, IT-57, IT 42, IT-58 and proteins labeled A- K) were selected and subjected to N-terminal amino acid sequencing (Table 3). Three of these proteins were found to conespond to previously defined products.
- the N- terminal amino acid sequence of the protein labeled D was identical to that of Ag85 B and C. This result was unexpected given that the IT-49 mAb failed to detect this protein and N-terminal amino acid analysis confirmed that those proteins reacting with IT-49 were members of the Ag85 complex.
- the protein labeled E had an N-terminal sequence identical to that of glutamine synthetase.
- a third protein which reacted with IT-52 was found to be identical to MPT 51.
- the protein labeled I possessed an N-terminal sequence with 72% identity to the amino terminus of an ⁇ -hydroxysteroid dehydrogenase from a Eubacterium species , and the protein labeled F was homologous to a deduced amino acid sequence for an open reading frame identified in the Mtb cosmid MTCY1 Al 1.
- Examples I and H show that a high molecular weight fraction of CFP of Mtb reacted with a preponderance of sera from TB patients and that this fraction was distinguished from other native fractions in that it possessed the product reactive to mAb IT-57.
- the protein cluster (including the 88 kDa protein GlcB) defined by IT-42 and IT-57 was excised from a 2-D polyacrylamide gel, digested with trypsin and the resulting peptides analyzed by LC- MS-MS.
- a second product sequenced was a 25 kDa protein with a pi of 5.34. Its N-terminal sequence (XPVM/LVXPGXEXXQDN, [SEQ ID NO: 100]) showed homology to an internal fragment (DPNLVFPGMEIRQDN, [SEQ ID NO: 105]) corresponding to open reading frame 28c of the Mtb cosmid MTCYl Al 1. Analysis of that deduced sequence revealed a signal peptidase I consensus sequence (Ala-Xaa-Ala) and an apparent signal peptide preceding the N-terminus of the 25 kDa protein sequenced above N-terminal sequencing of selected CFPs identified three novel products:
- the protein cluster which was recognized by mAbs IT-42 and IT-57 was a primary focus of this study. These proteins migrated at a molecular mass range of 82 - 85 kDa in one co- inventor's laboratory (or 88kDa in another co-inventor's laboratory) and a pi range of 5.12 - 5.19. Results described in Examples I, II and N referred to a CFP of approximately 88 kDa that reacted with 70% of sera from TB patients and demonstrated a specificity of 100%. Subsequent 2-D mapping coupled with 2-D western blot analysis showed these dominant antigens which induce early antibody responses in TB patients are the same as the proteins reactive with IT-57 and IT-42. As stated above, this antigen is referred to as the 88 kDa protein GlcB.
- coli lysogenized with ⁇ gtl 1 (IT- 57) and the LFCFP were separated by SDS-PAG ⁇ polyacrylamide on 10% gels, transferred to nitrocellulose filters and probed with mAb IT-57.
- the mAb IT-57 recognized an 88 kDa band in the LFCFP and in the lysate of E. coli lysogen of ⁇ gtl 1 (IT-57). No proteins in the lysate from the E. coli 1089 lysogenized with the wild type ⁇ gtl 1 reacted with the mAb
- the katG gene was excised from pMD31 with the enzymes Kpnl and Xbal to yield an insert of 2.9 kb.
- An insert of approximately 3.2 kb obtained after ⁇ coRI digestion of the DNA from ⁇ gtl 1 (IT-57) was used for hybridization with the katG gene.
- the 3.2 kb insert from ⁇ gtl 1 (IT-57) hybridized with itself and with both the uncut pMD31 vector containing the katG gene and the katG insert DNA itself (2.9 kb). Therefore, the 88 kDa antigen that reacted with mAb IT-57 was in fact the catalase/peroxidase protein.
- E. coli, the tG-negative BCG strain 35747 transformed with either the pMD31:Mtb katG or with the control pMD31 plasmid (vector control) were tested.
- the LFCFPs, crude lysates from the lysogen ⁇ gtl 1 (IT-57), lysogenic E. coli 1089 infected with wild-type ⁇ gtl 1 , katG negative BCG strain containing pMD31 Mtb katG and the katG-negative BCG containing pMD31 were separated by SDS-PAG ⁇ polyacrylamide on 10% gels.
- the fractionated proteins were transferred to nitrocellulose filters and probed with an anti-catalase/peroxidase polyclonal serum (obtained from Dr. Clifton Barry, Rocky Mountain Laboratories, NIAID, Hamilton, MT), mAb IT-57, mAb IT-42 and serum from an advanced TB patient.
- the anti-catalase/peroxidase polyclonal serum and the mAb IT-57 reacted strongly with an 88 kDa antigen in the LFCFP, in the Mtb katG containing M. bovis BCG and in E. coli ⁇ gtl 1 (IT-57).
- MAb IT-42 reacted with the same bands in the LFCFP and the Mtb katG BCG, but not with the 88 kDa protein expressed in E. coli.
- the serum from the TB patient recognized an 88 kDa antigen in the lysates of the katG-negative BCG strain. This is evidence that the seroreactive 88 kDa antigen is a novel protein which has not been previously described.
- the culture filtrate protein from a tetG-negative strain of Mtb was resolved as above by 2-D PAGE.
- the protein spot ("Spot 1") corresponding to the sero-reactive 88kDa protein was cut out of the gel and subject to an in-gel digestion with trypsin.
- the resulting tryptic peptides were extracted, applied to a C 18 RP-HPLC column, and eluted with an increasing concentration of acetonitrile.
- the peptides eluted in this manner were introduced directly into a Finnigan LCQ Electrospray mass spectrometer. (See Materials and Methods above for further details.)
- the molecular mass of each peptide was determined, as was the charge state, with a zoom-scan program.
- Protein pi (from 3.0 to 10.0) All 0
- Sample ID (comment): Magic Bullet digest Database searched: NCBInr.07.09.99 Molecular weight search (65000 - 97000 Da) selects 21170 entries. Full pi range: 324311 entries. Species search (MYCOBACTERIUM) selects 5990 entries. Combined molecular weight, pi and species searches select 333 entries. MS-Fit search selects 80 entries (results displayed for top 10 matches
- the protein was identified as GlcB (Z78020) of Mtb, which is believed to be the enzyme malate synthase based on sequence homology to known proteins of other bacteria.
- This protein has the Accession number CAB01465 on the NCBI Genbank database (based on Cole, S.T. et al, Nature 393:537-544 (1998), which describes the complete genome sequence of Mtb).
- the sequence of this protein is SEQ ID NO: 106 as provided above.
- the goal of this study was to determine the repertoire of antigens recognized by antibodies in TB patients in order to elucidate the human humoral response to Mtb and to evaluate the potential of these antigens as candidates for serodiagnosis. This was accomplished by immunoblotting Mtb H37Rv secreted antigens, which had been separated by 1- and 2- dimensional electrophoresis, with sera (E. co/ ⁇ -absorbed) from TB patients and healthy controls. Of the more than 200 secreted proteins of Mtb, only 26 elicited antibodies in TB patients.
- the identity of several of these antigens was determined based on (a) their reactivity with murine mAbs, (b) N-terminal amino acid sequencing and (c) liquid chromatography-mass spectrometry( ⁇ xample HI). Twelve of these 26 antigens were recognized by sera from patients with early, non-cavitary TB and by patients with advanced cavitary TB. Of these twelve antigens, five, including the 88 kDa antigen (Example I), the MPT32 and Ag 85C, reacted strongly with sera from TB; the other two antigens have yet to be identified. The present invention is directed to the development of serodiagnostic assays (as described herein) employing these antigens that elicit antibodies in both early and advanced TB patients.
- Serum samples from 33 HlV-negative individuals with confirmed pulmonary TB were included in the study. Twenty of these sera were provided by Dr. J. M. Phadtare (see Example I). Nineteen of these patients were smear-positive and all had radiological evidence of moderate to advanced cavitary lesions. All these patients were bled 4- 24 weeks after initiation of therapy.
- Control groups Twenty-three HIV nes , TB nes , healthy individuals were included as controls. Sixteen of these were PPD + (skin test) and the remaining 7 were PPD neg .
- Antigens Twenty-three HIV nes , TB nes , healthy individuals were included as controls. Sixteen of these were PPD + (skin test) and the remaining 7 were PPD neg .
- Example I Culture filtrates from log phase Mtb H 3 Rv were used as the source of secreted antigens as described in Example I (LAM-free culture filtrate proteins or CFPs).
- the LFCFP preparation contained over 200 proteins (Example m, supra).
- Antigens were size fractionated by loading onto a preparative polyacrylamide tube gel, and proteins were separated by electrophoresis using an increasing wattage gradient (model 491 Prep Cell; Bio-Rad, Hercules, CA.). Fractions were collected, assayed by SDS-PAGE and pooled according to molecular weights. Contaminating SDS was removed as described above.
- Example I Reactivity of each fraction with human sera and an extensive panel of murine mAbs to Mtb antigens are described in Example I. Immunoadsorption of sera against E. coli lysates was performed as described in Example I. All ELISA assays, described in Example I, were perfonned using sera previously immunoadsorbed on E. coli lysates.
- the 1-D and 2-D blots were blocked with 3% BSA in phosphate buffered saline (PBS) for 2 hrs, and washed for 1 hr with PBS/Tween 2% (wash buffer). Individual lanes containing fractionated LFCFPs were exposed overnight at 4° to individual sera (diluted 1:100 with 1% BSA in PBS). The blots containing the 2-D fractionated LFCFPs were probed with four different serum pools comprised of individual sera whose reactivity with the above antigen preparations were previously determined by ELISA.
- PBS phosphate buffered saline
- n number of individuals in each group
- Sera were grouped according to reactivity by ELISA with total LFCFPs, or the sized fraction containing the 38 kDa PstS or the 88 kDa seroreactive protein (Table 5).
- Group I includes sera from 16 PPD + and 7 PPD neg healthy controls, none of whom were positive in ELISA with any of these antigen preparations.
- Group II includes 9 TB patients who tested antibody negative with all three antigen preparations; five of these patients were smear-positive and had cavitary disease. The remaining four patients lacked cavitary lesions, but two of these four were smear-positive.
- Group III includes thirteen patients with antibodies to both the LFCFPs and the fraction containing the 88 kDa antigen, but not the fraction containing the 38 kDa antigen. Five of these patients were smear-positive and had pulmonary cavitations. An additional four were smear-positive but lacked any cavitary lesions. The remaining four were smear negative and had no cavitations. Group TV included eleven patients, all of whom had antibodies to all three antigen preparations; 10/11 were smear-positive and all had radiological evidence of moderate to advanced cavitary disease.
- the 30-32 and 65 kDa antigens were also recognized by sera of the 9 PPD + healthy controls, though only 3/9 sera in this group recognized the 26 kDa antigen, and one serum sample recognized an additional 68 kDa antigen.
- Group JJ tuberculous sera were antibody negative with all 3 antigen preparations by
- 2D-PAGE provides enhanced resolution of complex protein mixtures.
- the LFCFPs preparation resolves into about 200 different proteins by this method.
- a complete 2-D map of the total CFPs of Mtb is shown in US 6,245,331and WO 98/29132 (and discussed in Example HI).
- 2D immunoblots of the fractionated LFCFPs were probed with serum pools corresponding to patient groups I-TV. The reactivity of each serum pool was compared with the reactivity of murine mAbs to identify the antigens recognized by TB patients' sera (Table 6).
- the other two antigens reactive with all serum groups had molecular weights of 55 kDa (#114, 120) and 58 kDa (#86, 96, 105) and failed to react with the murine mAbs.
- the former antigen has been identified as the glutamine synthetase by ⁇ - group analysis (Example HI, above). These antigens may correspond to the 65 kDa antigen that was reactive with the individual sera on 1-D blots.
- a 26 kDa antigen (#19, 29) and a 46 kDa (#51) were reactive with the control sera (group I) and antibody positive TB sera (group IJJ and group IV), but failed to react with the antibody negative TB serum pool (group IJ).
- the former antigen 26 kDa, #19, 29 was identified as MPT64 based on reactivity with the murine mAb IT- 67 and may be the 26 kDa antigen recognized by several control sera on 1-D blots
- antigens correspond to the multiple bands in the 30 to 60 kDa region on the 1-D blots.
- a 85 kDa protein (#113, 124, IT-42, IT-57) was reactive with this serum pool, but no antigens corresponding to the 74 and 76 kDa antigens seen on 1-D blots were discernible on the 2-D blot.
- the 85 kDa antigen (#113, 124) on the 2-D immunoblots corresponds to the 88 kDa antigen GlcB (Example I and Example HI).
- the serum pool from group IN TB patients recognized 11 of 12 antigens that were reactive with the group IJJ serum pool (except the 28 kDa antigen, #77; Table 6B).
- the reactivity of the group IN serum pool however, with the 26 kDa (#170, MPT51), 31 kDa (#119, Ag 85C), 35 kDa (#66, PstS), 38/42 (#11, 14, MPT32), 49 kDa (#82; IT-58), 85 kDa (#113, 124) and the 104 kDa (#111) antigens, was stronger than with the group HI serum pool.
- the group IV pool was reactive with all four isomers recognized by murine mAb IT- 23.
- the group HI and IV serum pools Table 6B
- the latter group also reacted with eight additional antigens (Table 6C).
- the antigen with a molecular weight below 30 kDa was the 13/14 kDa protein (#23, 38, IT-12 and SA12, GroES).
- this serum pool recognized four new antigens, with the same 31 kDa molecular weight but differing in their pi values: 31 kDa (#15, 16, 22, 25), 31 kDa (#62), 31 kDa (#57) and 31 kDa (#37), and a fifth antigen of 38 kDa (#32). Of these only the 31 kDa (#15, 16, 22, 25) was reactive with the mAb IT-44, while the remaining 4 antigens have not been previously described.
- this pool reacted with a 66/72 kDa protein (#65, 79, mAb IT-40 and IT-41, DnaK), and an unidentified 79 kDa antigen (#78).
- coli lysates eliminates the cross-reactive antibodies that have hindered the definition of seroreactive antigens, hi addition, the 2-D analysis and mapping of each antigen as described herein has allowed precise definition of antigens that appear to be critical for rational design of serodiagnosis and at least 5 secreted proteins as useful serodiagnostic agents.
- Antibodies to one of these, the 88 kDa antigen GlcB, are present in 80% of the advanced and 50% of the early TB.
- MPT32 has also been suggested to have serodiagnostic potential (Espitia et al, 1995, supra) but not as an "early" antigen.
- the remaining 3 antigens, the 49 kDa (#82; IT-58), 31 kDa antigen (#119, Ag 85C), and the 26 kDa (#170, IT-52) have never been used for assessing seroreactivity in patients until the making of the present invention.
- the present inventors' laboratories have changed the Reference Number designation of some of the spots on the 2D gels shown in US 6,245,331 (12 June 2001) and WO 98/29132 (published 09 July 1998) from a numeric to an alpha (letter) labeling.
- the presence of one or more of these antigens, an epitope-bearing peptide thereof or a reactive variant of the peptide, in an immunodiagnostic preparation in combination with one or more of the five early antigens (or a peptide thereof) described above enhances the sensitivity of the diagnostic assay.
- MPT64 26 kDa, #19, 29
- group I Another protein currently being assessed as a serodiagnosis candidate is MPT64 (26 kDa, #19, 29) (Nerbon et al, 1993, supra) was reported to provide sensitivities of about 46% in active TB patients.
- MPT64 26 kDa, #19, 29
- group I the healthy controls
- the early antigens identified herein may not be the only early antigens secreted during Mtb growth in vivo. These antigens may be the only ones that are distinguishable because of their strongly seroreactive epitopes.
- Several antigens of Mtb were either up- or down-regulated when the organisms were grown intracellularly in macrophages. The present inventors propose that, in vivo, Mtb organisms produce only those proteins required for survival and growth under these particular conditions which may differ from the requirements during growth in culture media. It is noteworthy that several of the antigens that elicit antibodies relatively early in TB (based on reactivity with group HI sera), are implicated as having a role in pathogenesis in vivo.
- Ag 85 A, Ag 85C and MPT51 all belong to the family of secreted proteins which bind to fibronectin (Wiker et al, 1992, Scand. J. Immunol, supra)).
- MPT32 is homologous to a fibronectin-binding protein of leprae (Schorey, J.S. et al, 1995, Infect. Immun. 63:2652- 2657).
- the present inventors have identified seroreactive antigens which are useful for diagnostic assays for TB patients who are relatively early in disease progression, view of the expected homology of these antigens with similar proteins in other mycobacterial species, species-specific epitopes should now be defined for serodiagnostic uses. If the absence of detectable antibodies (by ELISA) is due to the formation of immune complexes in vivo (Grange, supra), the present invention provides methods to identify such complexes containing these antibodies. hi view of the large number of antigens secreted by replicating Mtb in culture, it is significant that such a small number of antigens are reactive with TB patient antibodies.
- any single antigen on the 2-D blots with pooled sera may represent reactivity with only some of the individual sera comprising the pool.
- individual sera were assessed for antibodies to two of the antigens identified by the group JJI serum pool, Ag 85C and MPT32 which the present inventors had purified. Reactivities with the purified 38 kDa PstS antigen and the 88 kDa antigen GlcB (in fraction 15) was also tested.
- HC healthy controls. HIV* patients with TB included those diagnosed before (pre) or at the time of (at) TB diagnosis. **Borderline values of OD
- the combination of smear and ELISA could diagnose 50/54 (93%) of the TB patients.
- the reactivity of the serum samples with the culture filtrate proteins of Mtb was evaluated by ELISA as described above.
- ELISA plates were coated overnight with 125 ⁇ l of a 4 ⁇ g/ml suspension of the culture filtrate proteins of Mtb at 4°C. The next morning, the plates were washed with PBS, and 125 ⁇ l of urine were added to each well. After 90 min., the plates were washed with PBS-Tween, and the bound antibody detected by anti-human IgG-Alkaline Phosphatase conjugate, and the substrate for the enzyme.
- Urine samples from the TB patients (tested undiluted) reacted with a similar profile of antigens, albeit less well.
- the 88 kDa protein GlcB was recognized by antibodies in both urine samples, but the reactivity of the urine samples with MPT 32, Ag 85C and MPT 51 could not be ascertained on 1-D blots.
- ELISA results showed that anti-MPT 32 antibodies are present in the urine. This suggests that the antibodies in the urine are directed against the same antigens as are those in the serum, although antibody titers are lower. Together, these results indicate that (1) Anti-mycobacterial antibodies are present in the urine of a significant proportion of smear positive (late)TB patients, thereby serving as the basis for a urine based diagnostic test for TB.
- a urine or urine/serum based diagnostic test for TB is performed using the same antigens of Mtb described herein (as well as others) including full length proteins, polyproteins, peptides, and peptide multimers, that are identified as seroreactive.
- proteins and peptides that are defined herein as being useful for serodiagnosis of TB or TB vaccines in humans can also be the basis of serodiagnostic assays and vaccines for TB in other mammals.
- the present invention is useful in the veterinary medical setting as well.
- the Hopp-Woods method was described in Hopp, TP & Woods, KR, Proc Natl Acad Sci USA, 1981, 75:3824-3828; Hopp & Woods, Mol Immunol, 1983 20:483-489).
- the method locates protein antigenic determinants by analyzing amino acid sequences in order to find the point of greatest local hydrophilicity. This is accomplished by assigning each amino acid a numerical value (hydrophilicity value) and then repetitively averaging these values along the peptide chain. The point of highest local average hydrophilicity is invariably located in, or immediately adjacent to, an antigenic determinant.
- the prediction success rate depends on averaging group length, with hexapeptide averages yielding optimal results.
- the method was originally developed using 12 proteins for which extensive immunochemical information was available and subsequently was used to predict antigenic determinants
- the 1983 publication describes a computerized method for predicting the locations of protein antigenic determinants which requires only amino acid sequence information. This procedure was used to predict the major antigenic determinant of the hepatitis B surface antigen, and is suitable for use on personal computers (having been written in BASIC to make it available to investigators with limited computer experience and/or resources.
- This document also demonstrated a means of locating multiple antigenic sites on a homologous series of proteins using influenza hemagglutinin. Another approach to analyze "flexibility" of the molecules is the Karplus-Stultz method
- DLD dynamic ligand design
- This package included a novel algorithm for the prediction of potential antigenic sites.
- the software package offers a powerful tool to analyze an amino acid sequence for antigenic site analyses.
- Results are shown in Table 10, below which records the peptides to which reactivity was observed. Reactivity is indicated as the fraction of TB sera that reacted positively (absorbance >2.5 standard deviations above the negative control sera). Sera were assayed against the peptides at multiple dilutions; optimal responses were usually observed at a 1/10 dilution, though 1/5 and 1/20 dilutions were also tested.
- a custom library of 13-mer peptides, overlapping by 7 amino acids, and attached covalently to a pre-derivatized cellulose membrane was synthesized by Sigma Genosys in accordance with the present inventors' instructions.
- the sequences of the 122 peptides, spanning the entire protein are shown in Table 11, below.
- the membrane was used for colorimetric detection of immunoreactivity. After regeneration, the free immobilized peptides are "regenerated” and a second and subsequent antibody or antiserum is applied. Thus, different patterns are obtained on the identical peptide matrix and can be compared qualitatively and quantitatively.
- the membrane was rinsed briefly in methanol, and washed thrice (10 min each) in Tris-buffered saline. The membrane was blocked overnight at room temperature with a casein-containing blocking agent provided by the Sigma Genosys. After blocking, the membrane was washed with Tris-buffered saline containing Tween-20 (0.05%) and exposed to 1:100 dilution of a serum pool prepared from sera of 6 patients with confirmed, smear-positive TB.
- the overlapping peptide library was incubated with the pooled serum for 4 hrs, washed and probed with la :200 dilution of ⁇ -galactosidase-conjugated anti-human IgG. After this incubation the membrane was washed and exposed to the substrate for ⁇ -galactosidase (X-gal in N,N'-dimethyl formamide (DMF).
- the membrane could be regenerated for reuse by washing extensively in deionized water (30 min, 3 changes), and then in DMF before stripping with buffer A (urea 48% w/v, SDS, 1% w/v, and ⁇ -mercaptoethanol, 1/1000 dilution of the neat reagent) and buffer B (50% ethanol /10% acetic acid (v/v)).
- buffer A urea 48% w/v, SDS, 1% w/v, and ⁇ -mercaptoethanol, 1/1000 dilution of the neat reagent
- buffer B 50% ethanol /10% acetic acid (v/v)
- the membrane was probed with the ⁇ -galactosidase-conjugated anti-human IgG (without prior exposure to the human serum) to identify peptides that bind non-specifically to the secondary antibody (or enzyme). Based on the reactivity of the 122 overlapping peptides (SEQ ID NO:l 16-237) with the pooled sera, the following peptides were identified as being strongly immunogenic in TB patients: SEQ ID NO:117; SEQ ID NO:126; SEQ ID NO:127; SEQ ID NO:128; SEQ ID NO:134; SEQ ID NO:135;SEQ ID NO:136; SEQ ID NO:137; SEQ ID NO:138; SEQ ID NO:154; SEQ ID NO:155; SEQ ID NO:170; SEQ ID NO:172; SEQ ID NO:191; SEQ ID NO:216; and SEQ ID NO:217.
- sequences represent peptides that comprise strongly recognized epitopes (2-5x more intense staining with TB serum pool vs. control. This is in addition to those epitopes identified earlier on the basis of computer algorithms and found to be immunogenic in patients (see Example IX).
- the references cited above are all incorporated by reference herein, whether specifically incorporated or not.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002324578A AU2002324578B2 (en) | 2001-08-02 | 2002-08-02 | Early detection of mycobacterial disease using peptides |
EP02759228A EP1463526A4 (en) | 2001-08-02 | 2002-08-02 | Early detection of mycobacterial disease using peptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30918501P | 2001-08-02 | 2001-08-02 | |
US60/309,185 | 2001-08-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003012395A2 true WO2003012395A2 (en) | 2003-02-13 |
WO2003012395A3 WO2003012395A3 (en) | 2004-07-22 |
Family
ID=23197061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/024297 WO2003012395A2 (en) | 2001-08-02 | 2002-08-02 | Early detection of mycobacterial disease using peptides |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1463526A4 (en) |
CN (1) | CN1694725A (en) |
AU (1) | AU2002324578B2 (en) |
WO (1) | WO2003012395A2 (en) |
ZA (1) | ZA200400843B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100415771C (en) * | 2006-06-06 | 2008-09-03 | 中国人民解放军第二军医大学 | Antigen epitope for exciting human anti-tubercle bacillus protective immunoreaction and its use |
WO2009129521A3 (en) * | 2008-04-19 | 2010-02-18 | New York University | Immunodominant mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization |
CN101311189B (en) * | 2006-06-06 | 2010-09-08 | 中国人民解放军第二军医大学 | Antigen epitope for exciting protective immunity against tubercle bacillus of human body and uses thereof |
CN101298471B (en) * | 2006-06-06 | 2011-01-19 | 中国人民解放军第二军医大学 | Epitope capable of exciting human body anti-mycobacterium tuberculosis protective immunity reaction and use thereof |
WO2012177520A3 (en) * | 2011-06-20 | 2013-04-04 | Matthias Rath | Oligopeptides and their use for treating infectious diseases |
US20150253324A1 (en) * | 2014-03-07 | 2015-09-10 | Institute For Systems Biology | Point of care assays to detect the status of tuberculosis infection |
US11268954B2 (en) | 2015-03-31 | 2022-03-08 | Sysmex Corporation | Immunoassay apparatus |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2307402B1 (en) * | 2006-10-30 | 2009-09-30 | Archivel Farma, S.L. | PROFILACTIC VACCINE AGAINST TUBERCULOSIS. |
WO2009089535A2 (en) * | 2008-01-11 | 2009-07-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Polypeptide vaccine and vaccination strategy against mycobacterium |
CN101235090B (en) * | 2008-01-31 | 2012-02-22 | 复旦大学 | Specificity fusion protein applied to tuberculosis rapid diagnosis and its construction method |
CN102675425B (en) * | 2011-04-22 | 2013-12-04 | 中国医学科学院病原生物学研究所 | Functional mycobacterium tuberculosis antigen polypeptide and application thereof |
JP2021508836A (en) * | 2017-12-22 | 2021-03-11 | スゲンテック, インク.Sugentech, Inc. | Tuberculosis diagnostic method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5330754A (en) * | 1992-06-29 | 1994-07-19 | Archana Kapoor | Membrane-associated immunogens of mycobacteria |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2144394T3 (en) * | 1989-09-19 | 2000-06-16 | Innogenetics Nv | RECOMBINANT POLYPEPTIDES AND PEPTIDES, NUCLEIC ACIDS THAT CODE THEM AND USE OF SUCH POLYPEPTIDES AND PEPTIDES FOR THE DIAGNOSIS OF TUBERCULOSIS. |
DE4440118C1 (en) * | 1994-11-11 | 1995-11-09 | Forschungszentrum Juelich Gmbh | Gene expression in coryneform bacteria regulating DNA |
US6290969B1 (en) * | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6245331B1 (en) * | 1997-01-02 | 2001-06-12 | New York Univ. Medical Center | Early detection of mycobacterial disease |
AU746752B2 (en) * | 1996-12-31 | 2002-05-02 | Colorado State University Research Foundation | Early detection of mycobacterial disease |
ATE382368T1 (en) * | 1997-01-21 | 2008-01-15 | Univ California | EPITOPES OF AN EXTRACELLULAR ANTIGEN |
US20030027774A1 (en) * | 1999-03-18 | 2003-02-06 | Ronald C. Hendrickson | Tuberculosis antigens and methods of use therefor |
JP2003517291A (en) * | 1999-06-25 | 2003-05-27 | ビーエーエスエフ アクチェンゲゼルシャフト | Corynebacterium glutamicum gene encoding a protein involved in carbon metabolism and energy production |
US7311922B1 (en) * | 1999-10-07 | 2007-12-25 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
-
2002
- 2002-08-02 WO PCT/US2002/024297 patent/WO2003012395A2/en not_active Application Discontinuation
- 2002-08-02 CN CN02819446.2A patent/CN1694725A/en active Pending
- 2002-08-02 ZA ZA200400843A patent/ZA200400843B/en unknown
- 2002-08-02 AU AU2002324578A patent/AU2002324578B2/en not_active Ceased
- 2002-08-02 EP EP02759228A patent/EP1463526A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5330754A (en) * | 1992-06-29 | 1994-07-19 | Archana Kapoor | Membrane-associated immunogens of mycobacteria |
Non-Patent Citations (2)
Title |
---|
BASSEY E.O.E. ET AL.: 'Candidate antigens for improved serodiagnosis of tuberculosis' TUBERCLE AND LUNG DISEASE vol. 77, no. 2, April 1996, pages 136 - 145, XP004540072 * |
See also references of EP1463526A2 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100415771C (en) * | 2006-06-06 | 2008-09-03 | 中国人民解放军第二军医大学 | Antigen epitope for exciting human anti-tubercle bacillus protective immunoreaction and its use |
CN101311189B (en) * | 2006-06-06 | 2010-09-08 | 中国人民解放军第二军医大学 | Antigen epitope for exciting protective immunity against tubercle bacillus of human body and uses thereof |
CN101298471B (en) * | 2006-06-06 | 2011-01-19 | 中国人民解放军第二军医大学 | Epitope capable of exciting human body anti-mycobacterium tuberculosis protective immunity reaction and use thereof |
WO2009129521A3 (en) * | 2008-04-19 | 2010-02-18 | New York University | Immunodominant mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization |
US9335325B2 (en) | 2008-04-19 | 2016-05-10 | New York University | Immunodominant Mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization |
WO2012177520A3 (en) * | 2011-06-20 | 2013-04-04 | Matthias Rath | Oligopeptides and their use for treating infectious diseases |
US20150253324A1 (en) * | 2014-03-07 | 2015-09-10 | Institute For Systems Biology | Point of care assays to detect the status of tuberculosis infection |
US9726667B2 (en) * | 2014-03-07 | 2017-08-08 | Institute For Systems Biology | Point of care assays to detect the status of tuberculosis infection |
US11268954B2 (en) | 2015-03-31 | 2022-03-08 | Sysmex Corporation | Immunoassay apparatus |
Also Published As
Publication number | Publication date |
---|---|
CN1694725A (en) | 2005-11-09 |
AU2002324578B2 (en) | 2009-02-05 |
EP1463526A2 (en) | 2004-10-06 |
ZA200400843B (en) | 2007-11-28 |
EP1463526A4 (en) | 2006-08-30 |
WO2003012395A3 (en) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6506384B1 (en) | Early detection of mycobacterial disease | |
US6245331B1 (en) | Early detection of mycobacterial disease | |
US7776341B2 (en) | Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens | |
US7122196B2 (en) | Compounds and methods for diagnosis of tuberculosis | |
EP2154248B1 (en) | Compounds and methods for diagnosis of tuberculosis | |
Van Gelder et al. | Serodiagnosis of toxoplasmosis by using a recombinant form of the 54-kilodalton rhoptry antigen expressed in Escherichia coli | |
KR20010012813A (en) | Compounds for diagnosis of tuberculosis and methods for their use | |
Roche et al. | T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of Mycobacterium bovis | |
AU2002324578B2 (en) | Early detection of mycobacterial disease using peptides | |
WO2008029981A1 (en) | Diagnostic formulation for tsutsugamushi disease | |
US7745141B2 (en) | Mycobacterial proteins as early antigens for serodiagnosis and vaccines | |
US9335325B2 (en) | Immunodominant Mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization | |
AU2002324578A1 (en) | Early detection of mycobacterial disease using peptides | |
US7807182B2 (en) | Early detection of mycobacterial disease using peptides | |
Kanagavel et al. | B-cell-specific peptides of Leptospira interrogans LigA for diagnosis of patients with acute leptospirosis | |
AU746752B2 (en) | Early detection of mycobacterial disease | |
WO1998029132A9 (en) | Early detection of mycobacterial disease | |
JP6698530B2 (en) | Diagnostic reagents for improving in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis | |
Falla et al. | Identification of B-and T-cell epitopes within the MTP40 protein of Mycobacterium tuberculosis and their correlation with the disease course | |
CN107530414B (en) | Mycobacterium tuberculosis antigen for distinguishing active tuberculosis infection and latent tuberculosis infection and application thereof | |
WO2008010096A2 (en) | Method for preparing recombinant mycobacterial polypeptides in yeast and their use in diagnosis of mycobacterial related diseases | |
Florio et al. | Identification, molecular cloning, and evaluation of potential use of isocitrate dehydrogenase II of Mycobacterium bovis BCG in serodiagnosis of tuberculosis | |
EP1712629A2 (en) | Compounds and methods for diagnosis of tuberculosis | |
CA2591804A1 (en) | Method for preparing recombinant mycobacterial polypeptides in yeast and their use in diagnosis of mycobacterial related diseases | |
BRPI1106311A2 (en) | use of mycobacterium leprae mimetic peptides for diagnosis and vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002324578 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/00843 Country of ref document: ZA Ref document number: 200400843 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 199/KOLNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002759228 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028194462 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002759228 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |